An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane.
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, csf, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS.
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.
Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.
Agents inhibiting the effect of narcotics on the central nervous system.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
An integrin beta subunit of approximately 85-kDa in size which has been found in INTEGRIN ALPHAIIB-containing and INTEGRIN ALPHAV-containing heterodimers. Integrin beta3 occurs as three alternatively spliced isoforms, designated beta3A-C.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS.
Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.
A family of hexahydropyridines.
Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS.
Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.
Compounds that selectively bind to and block the activation of ADENOSINE A2 RECEPTORS.
Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Compounds that bind to and block the stimulation of ADENOSINE A1 RECEPTORS.
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
Established cell cultures that have the potential to propagate indefinitely.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.
A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.
A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-2 receptors are more sensitive to EPINEPHRINE than to NOREPINEPHRINE and have a high affinity for the agonist TERBUTALINE. They are widespread, with clinically important roles in SKELETAL MUSCLE; LIVER; and vascular, bronchial, gastrointestinal, and genitourinary SMOOTH MUSCLE.
An integrin found in FIBROBLASTS; PLATELETS; MONOCYTES, and LYMPHOCYTES. Integrin alpha5beta1 is the classical receptor for FIBRONECTIN, but it also functions as a receptor for LAMININ and several other EXTRACELLULAR MATRIX PROTEINS.
Drugs that bind to but do not activate GABA-A RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-A RECEPTOR AGONISTS.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS.
Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
Also known as CD104 antigen, this protein is distinguished from other beta integrins by its relatively long cytoplasmic domain (approximately 1000 amino acids vs. approximately 50). Five alternatively spliced isoforms have been described.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
This intrgrin is a key component of HEMIDESMOSOMES and is required for their formation and maintenance in epithelial cells. Integrin alpha6beta4 is also found on thymocytes, fibroblasts, and Schwann cells, where it functions as a laminin receptor (RECEPTORS, LAMININ) and is involved in wound healing, cell migration, and tumor invasiveness.
Integrin alpha4beta1 is a FIBRONECTIN and VCAM-1 receptor present on LYMPHOCYTES; MONOCYTES; EOSINOPHILS; NK CELLS and thymocytes. It is involved in both cell-cell and cell- EXTRACELLULAR MATRIX adhesion and plays a role in INFLAMMATION, hematopoietic cell homing and immune function, and has been implicated in skeletal MYOGENESIS; NEURAL CREST migration and proliferation, lymphocyte maturation and morphogenesis of the PLACENTA and HEART.
Integrin beta chains combine with integrin alpha chains to form heterodimeric cell surface receptors. Integrins have traditionally been classified into functional groups based on the identity of one of three beta chains present in the heterodimer. The beta chain is necessary and sufficient for integrin-dependent signaling. Its short cytoplasmic tail contains sequences critical for inside-out signaling.
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives.
Drugs that selectively bind to but do not activate HISTAMINE H3 RECEPTORS. They have been used to correct SLEEP WAKE DISORDERS and MEMORY DISORDERS.
A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
An integrin found on fibroblasts, platelets, endothelial and epithelial cells, and lymphocytes where it functions as a receptor for COLLAGEN and LAMININ. Although originally referred to as the collagen receptor, it is one of several receptors for collagen. Ligand binding to integrin alpha2beta1 triggers a cascade of intracellular signaling, including activation of p38 MAP kinase.
Elements of limited time intervals, contributing to particular results or situations.
Drugs that selectively bind to and activate beta-adrenergic receptors.
A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)
Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells.
A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.
The rate dynamics in chemical or physical systems.
Drugs that bind to and block the activation of ADRENERGIC BETA-2 RECEPTORS.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.
Peptides composed of between two and twelve amino acids.
Proteins prepared by recombinant DNA technology.
A family of transmembrane glycoproteins (MEMBRANE GLYCOPROTEINS) consisting of noncovalent heterodimers. They interact with a wide variety of ligands including EXTRACELLULAR MATRIX PROTEINS; COMPLEMENT, and other cells, while their intracellular domains interact with the CYTOSKELETON. The integrins consist of at least three identified families: the cytoadhesin receptors(RECEPTORS, CYTOADHESIN), the leukocyte adhesion receptors (RECEPTORS, LEUKOCYTE ADHESION), and the VERY LATE ANTIGEN RECEPTORS. Each family contains a common beta-subunit (INTEGRIN BETA CHAINS) combined with one or more distinct alpha-subunits (INTEGRIN ALPHA CHAINS). These receptors participate in cell-matrix and cell-cell adhesion in many physiologically important processes, including embryological development; HEMOSTASIS; THROMBOSIS; WOUND HEALING; immune and nonimmune defense mechanisms; and oncogenic transformation.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.
The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
Compounds with BENZENE fused to AZEPINES.
Integrin beta-1 chains which are expressed as heterodimers that are noncovalently associated with specific alpha-chains of the CD49 family (CD49a-f). CD29 is expressed on resting and activated leukocytes and is a marker for all of the very late activation antigens on cells. (from: Barclay et al., The Leukocyte Antigen FactsBook, 1993, p164)
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Compounds that selectively bind to and block the activation of ADENOSINE A3 RECEPTORS.
A group of compounds that contain the structure SO2NH2.
Glycoproteins which contain sialic acid as one of their carbohydrates. They are often found on or in the cell or tissue membranes and participate in a variety of biological activities.
A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The beta-3 adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
A subtype of endothelin receptor found predominantly in the VASCULAR SMOOTH MUSCLE. It has a high affinity for ENDOTHELIN-1 and ENDOTHELIN-2.
A cell surface receptor mediating cell adhesion to the EXTRACELLULAR MATRIX and to other cells via binding to LAMININ. It is involved in cell migration, embryonic development, leukocyte activation and tumor cell invasiveness. Integrin alpha6beta1 is the major laminin receptor on PLATELETS; LEUKOCYTES; and many EPITHELIAL CELLS, and ligand binding may activate a number of signal transduction pathways. Alternative splicing of the cytoplasmic domain of the alpha6 subunit (INTEGRIN ALPHA6) results in the formation of A and B isoforms of the heterodimer, which are expressed in a tissue-specific manner.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
One of the ESTROGEN RECEPTORS that has greater affinity for ISOFLAVONES than ESTROGEN RECEPTOR ALPHA does. There is great sequence homology with ER alpha in the DNA-binding domain but not in the ligand binding and hinge domains.
Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Purine bases found in body tissues and fluids and in some plants.
Compounds that bind to and block the stimulation of PURINERGIC P2X RECEPTORS. Included under this heading are antagonists for specific P2X receptor subtypes.
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses.
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.
A glycogen synthase kinase that was originally described as a key enzyme involved in glycogen metabolism. It regulates a diverse array of functions such as CELL DIVISION, microtubule function and APOPTOSIS.
Seven membered heterocyclic rings containing a NITROGEN atom.
Integrin alpha1beta1 functions as a receptor for LAMININ and COLLAGEN. It is widely expressed during development, but in the adult is the predominant laminin receptor (RECEPTORS, LAMININ) in mature SMOOTH MUSCLE CELLS, where it is important for maintenance of the differentiated phenotype of these cells. Integrin alpha1beta1 is also found in LYMPHOCYTES and microvascular endothelial cells, and may play a role in angiogenesis. In SCHWANN CELLS and neural crest cells, it is involved in cell migration. Integrin alpha1beta1 is also known as VLA-1 and CD49a-CD29.
A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.
Drugs that bind to and block the activation of PURINERGIC RECEPTORS.
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
Use of electric potential or currents to elicit biological responses.
The observable response an animal makes to any situation.
Adherence of cells to surfaces or to other cells.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
A class of cell surface receptors for TACHYKININS with a preference for SUBSTANCE P. Neurokinin-1 (NK-1) receptors have been cloned and are members of the G protein coupled receptor superfamily. They are found on many cell types including central and peripheral neurons, smooth muscle cells, acinar cells, endothelial cells, fibroblasts, and immune cells.
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
Compounds that inhibit the action of prostaglandins.
Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.
1,4-Diethylene dioxides. Industrial solvents. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), dioxane itself may "reasonably be anticipated to be a carcinogen." (Merck Index, 11th ed)
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.
A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Injections into the cerebral ventricles.
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known.
Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed)
Drugs that bind to but do not activate GABA-B RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-B RECEPTOR AGONISTS.
A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
A subclass of cannabinoid receptor found primarily on central and peripheral NEURONS where it may play a role modulating NEUROTRANSMITTER release.
Specific molecular sites or proteins on or in cells to which VASOPRESSINS bind or interact in order to modify the function of the cells. Two types of vasopressin receptor exist, the V1 receptor in the vascular smooth muscle and the V2 receptor in the kidneys. The V1 receptor can be subdivided into V1a and V1b (formerly V3) receptors.
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. They share a common structure and signal through HETEROTRIMERIC G-PROTEINS.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine.
A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)
A subtype of endothelin receptor found predominantly in the KIDNEY. It may play a role in reducing systemic ENDOTHELIN levels.
Cell surface proteins that bind cholecystokinin (CCK) with high affinity and trigger intracellular changes influencing the behavior of cells. Cholecystokinin receptors are activated by GASTRIN as well as by CCK-4; CCK-8; and CCK-33. Activation of these receptors evokes secretion of AMYLASE by pancreatic acinar cells, acid and PEPSIN by stomach mucosal cells, and contraction of the PYLORUS and GALLBLADDER. The role of the widespread CCK receptors in the central nervous system is not well understood.
An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.
An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.
An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.
Cell surface receptors that bind BRADYKININ and related KININS with high affinity and trigger intracellular changes which influence the behavior of cells. The identified receptor types (B-1 and B-2, or BK-1 and BK-2) recognize endogenous KALLIDIN; t-kinins; and certain bradykinin fragments as well as bradykinin itself.
An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.
Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop.
A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter.
A class of cell surface receptors that prefer ADENOSINE to other endogenous PURINES. Purinergic P1 receptors are widespread in the body including the cardiovascular, respiratory, immune, and nervous systems. There are at least two pharmacologically distinguishable types (A1 and A2, or Ri and Ra).
The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Brain waves with frequency between 15-30 Hz seen on EEG during wakefulness and mental activity.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
A class of opioid receptors recognized by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins.
A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.
A class of cell surface receptors for tachykinins that prefers neurokinin A; (NKA, substance K, neurokinin alpha, neuromedin L), neuropeptide K; (NPK); or neuropeptide gamma over other tachykinins. Neurokinin-2 (NK-2) receptors have been cloned and are similar to other G-protein coupled receptors.
An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
A class of saturated compounds consisting of two rings only, having two or more atoms in common, containing at least one hetero atom, and that take the name of an open chain hydrocarbon containing the same total number of atoms. (From Riguady et al., Nomenclature of Organic Chemistry, 1979, p31)
Compounds with a BENZENE fused to IMIDAZOLES.
Drugs that bind to and block the activation of ADRENERGIC BETA-3 RECEPTORS.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
Single chains of amino acids that are the units of multimeric PROTEINS. Multimeric proteins can be composed of identical or non-identical subunits. One or more monomeric subunits may compose a protomer which itself is a subunit structure of a larger assembly.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
Cell surface receptors that are specific for INTERLEUKIN-1. Included under this heading are signaling receptors, non-signaling receptors and accessory proteins required for receptor signaling. Signaling from interleukin-1 receptors occurs via interaction with SIGNAL TRANSDUCING ADAPTOR PROTEINS such as MYELOID DIFFERENTIATION FACTOR 88.
Drugs that selectively bind to and activate alpha adrenergic receptors.
Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system.
The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES.
A cell line derived from cultured tumor cells.
One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
The most common inhibitory neurotransmitter in the central nervous system.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
A DNA repair enzyme that catalyzes DNA synthesis during base excision DNA repair. EC
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.

Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. (1/4656)

Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors.  (+info)

Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. (2/4656)

Norepinephrine (NE) reuptake function is impaired in heart failure and this may participate in myocyte hyperstimulation by the neurotransmitter. This alteration can be assessed by 123I-metaiodobenzylguanidine (MIBG) scintigraphy. METHODS: To determine whether the impairment of neuronal NE reuptake was reversible after metoprolol therapy, we studied 18 patients (43+/-7 y) with idiopathic dilated cardiomyopathy who were stabilized at least for 3 mo with captopril and diuretics. Patients underwent, before and after 6 mo of therapy with metoprolol, measurements of radionuclide left ventricular ejection fraction (LVEF), maximal oxygen consumption and plasma NE concentration. The cardiac adrenergic innervation function was scintigraphically assessed with MIBG uptake and release measurements on the planar images obtained 20 min and 4 h after tracer injection. To evaluate whether metoprolol had a direct interaction with cardiac MIBG uptake and release, six normal subjects were studied before and after a 1-mo metoprolol intake. RESULTS: In controls, neither cardiac MIBG uptake and release nor circulating NE concentration changed after the 1-mo metoprolol intake. Conversely, after a 6-mo therapy with metoprolol, patients showed increased cardiac MIBG uptake (129%+/-10% versus 138%+/-17%; P = 0.009), unchanged cardiac MIBG release and decreased plasma NE concentration (0.930+/-412 versus 0.721+/-0.370 ng/mL; P = 0.02). In parallel, patients showed improved New York Heart Association class (2.44+/-0.51 versus 2.05+/-0.23; P = 0.004) and increased LVEF (20%+/-8% versus 27%+/-8%; P = 0.0005), whereas maximal oxygen uptake remained unchanged. CONCLUSION: Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation.  (+info)

QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. (3/4656)

OBJECTIVE: To compare QT dispersion in patients with impaired left ventricular systolic function and in matched control patients with normal left ventricular systolic function. DESIGN: A retrospective, case-control study with controls matched 4:1 for age, sex, previous myocardial infarction, and diuretic and beta blocker treatment. SETTING: A regional cardiology centre and a university teaching hospital. PATIENTS: 25 patients with impaired left ventricular systolic function and 100 patients with normal left ventricular systolic function. MAIN OUTCOME MEASURES: QT and QTc dispersion measured by three methods: the difference between maximum and minimum QT and QTc intervals, the standard deviation of QT and QTc intervals, and the "lead adjusted" QT and QTc dispersion. RESULTS: All measures of QT/QTc dispersion were closely interrelated (r values 0.86 to 0.99; all p < 0.001). All measures of QT and QTc dispersion were significantly increased in the patients with impaired left ventricular systolic function v controls (p < 0.001): 71.9 (6.5) (mean (SEM)) v 46.9 (1.7) ms for QT dispersion, and 83.6 (7.6) v 54.3 (2.1) ms(-1-2) for QTc dispersion. All six dispersion parameters were reduced in patients taking beta blockers (p < 0.05), regardless of whether left ventricular function was normal or impaired-by 9.4 (4.6) ms for QT dispersion (p < 0.05) and by 13.8 (6. 5) ms(-1-2) for QTc dispersion (p = 0.01). CONCLUSIONS: QT and QTc dispersion are increased in patients with systolic heart failure in comparison with matched controls, regardless of the method of measurement and independently of possible confounding factors. beta Blockers are associated with a reduction in both QT and QTc dispersion, raising the possibility that a reduction in dispersion of ventricular repolarisation may be an important antiarrhythmic mechanism of beta blockade.  (+info)

AV reentrant and idiopathic ventricular double tachycardias: complicated interactions between two tachycardias. (4/4656)

An electrophysiological study was performed in a 61 year old man with Wolff- Parkinson-White (WPW) syndrome. At baseline, neither ventricular nor supraventricular tachycardias could be induced. During isoprenaline infusion, ventricular tachycardia originating from the right ventricular outflow tract (RVOT) with a cycle length of 280 ms was induced and subsequently atrioventricular reentrant tachycardia (AVRT) with a cycle length of 300 ms using an accessory pathway in the left free wall appeared. During these tachycardias, AVRT was entrained by ventricular tachycardia. The earliest ventricular activation site during the ventricular tachycardia was determined to be the RVOT site and a radiofrequency current at 30 W successfully ablated the ventricular tachycardia at this site. The left free wall accessory pathway was also successfully ablated during right ventricular pacing. The coexistence of WPW syndrome and cathecolamine sensitive ventricular tachycardia originating from the RVOT has rarely been reported. Furthermore, the tachycardias were triggered by previous tachycardias.  (+info)

Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. (5/4656)

The long-acting beta2 sympathomimetics salmeterol and formoterol have been presumed to exert their prolonged action either by binding to an accessory binding site ("exo-site") near the beta2 adrenoceptor or by their high affinity for beta2 adrenoceptors and correspondingly slow dissociation. Whereas most studies with salmeterol had been done in intact tissues, which have slow diffusion and compartmentation of drugs in lipophilic phases, that restrict drug access to the receptor biophase, we used purified receptor membranes from rat lung and disaggregated calf tracheal myocytes as model systems. Binding experiments were designed to measure the slow dissociation of agonists by means of delayed association of (-)-[125I]iodopindolol. Rat lung membranes were pretreated with high concentrations of agonists (salmeterol, formoterol, isoprenaline) before dissociation was induced by 50-fold dilution. Half-times of association of (-)-[125I]iodopindolol remained unchanged compared with untreated controls, indicating that dissociation of agonists occurred in less than 2 min. Adenylyl cyclase experiments were designed to determine the on and off kinetics of agonists to beta2 adrenoceptors by measuring the rate of receptor-induced cyclic AMP (cAMP) formation. Experiments were performed in tracheal membranes characterized by high Vmax values of cAMP formation. Adenylyl cyclase activation occurred simultaneously with the addition of the agonist, continued linearly with time for 60 min, and ceased immediately after the antagonist was added. Similarly, when receptor membranes were preincubated in a small volume with high salmeterol concentrations, there was a linear increase in cAMP formation, which was immediately interrupted by a 100-fold dilution of the reaction mixture. This militates against the exo-site hypothesis. On the other hand, dissociation by dilution was much less when membranes were preincubated with a large volume of salmeterol at the same concentration, indicating that physicochemical effects, and not exo-site binding, underlie its prolonged mode of action.  (+info)

Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. (6/4656)

Prostaglandin (PG) release in cells expressing constitutive cyclooxygenase-1 is known to be regulated by liberation of arachidonic acid by phospholipase A2 followed by metabolism by cyclooxygenase. However, the relative contribution of phospholipase A2 to the release of PGs in cells expressing cyclooxygenase-2 is not clear. We addressed this question by using radioimmunoassay to measure PGE2 release by human cells (A549) induced to express cyclooxygenase-2 (measured by Western blot analysis) by interleukin-1beta. Cells were either unstimulated or stimulated with agents known to activate phospholipase A2 (bradykinin, Des-Arg10-kallidin, or the calcium ionophore A23187) or treated with exogenous arachidonic acid. When cells were treated to express cyclooxygenase-2, the levels of PGE2 released over 15 min were undetectable; however, in the same cells stimulated with bradykinin, A23187, or arachidonic acid, large amounts of prostanoid were produced. Using selective inhibitors/antagonists, we found that the effects of bradykinin were mediated by B2 receptor activation and that prostanoid release was due to cyclooxygenase-2, and not cyclooxygenase-1, activity. In addition, we show that the release of PGE2 stimulated by either bradykinin, A23187, or arachidonic acid was inhibited by the phospholipase A2 inhibitor arachidonate trifluoromethyl ketone. Hence, we have demonstrated that PGE2 is released by two components: induction of cyclooxygenase-2 and supply of substrate, probably via activation of phospholipase A2. This is illustrated in A549 cells by a clear synergy between the cytokine interleukin-1beta and the kinin bradykinin.  (+info)

Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. (7/4656)

The purpose of the present study was to confirm the presence of beta3-adrenoceptor subtype in the relaxation of human urinary bladder detrusor tissue by reverse transcription-polymerase chain reaction (PCR); direct sequencing of the PCR product, in situ hybridization; and isometric contraction. Using reverse transcription-PCR, the mRNAs of three receptor subtypes (beta1, beta2, and beta3) were expressed in the human urinary bladder detrusor tissue. Direct sequencing of the PCR product of the above beta3-adrenoceptor revealed no mutation in the amplified regions. In situ hybridization with digoxygenin-labeled oligonucleotide probe revealed the presence of the mRNA of beta3-adrenoceptor subtype in the smooth muscle of the urinary bladder. The relaxant effects of isoproterenol (a nonselective beta-adrenoceptor agonist); ZD7114, BRL37344, and CGP12177A (putative selective beta3-adrenoceptor agonists); and SR59230A (a putative selective beta3-adrenoceptor antagonist) were tested using an isometric contraction technique. Isoproterenol in either the presence or absence of both atenolol (a beta1-adrenoceptor-selective antagonist) and butoxamine (a beta2-adrenoceptor-selective antagonist) revealed a relaxant effect on the carbachol-induced contraction of the human urinary bladder detrusor. Both BRL37344 and CGP12177A also revealed relaxant effects on the human urinary bladder detrusor, but ZD7114 did not elicit any relaxation. These results suggest that beta3-adrenoceptor may have some role in urine storage in the human urinary bladder.  (+info)

Adrenoreceptors of the guinea-pig urinary bladder. (8/4656)

1 Adrenaline, noradrenaline and isoprenaline (5 mug/ml) did not affect the resting tone of the isolated urinary bladder of the guinea-pig. 2 The catecholamines (1-2 mug/ml) inhibited neuronally evoked contractions at various stimulation frequencies; the inhibition was maximum at 2 Hz and minimum at 50 Hz. Isoprenaline produced maximum inhibition. 3 Propranolol (0.5 mug/ml) completely blocked the catecholamine-induced inhibition at all the frequencies employed. The concentration-response curves of isoprenaline at 2, 10 and 50 Hz were characteristically shifted by propranolol (50 ng/ml). Phenoxybenzamine (0.2 mug/ml) was totally ineffective. 4 In some experiments adrenaline significantly raised the tone of the bladder exposed to propranolol; this effect could be blocked by phenoxybenzamine. 5 Acetylcholine-induced bladder contractions were inhibited by adrenaline (2 mug/ml); the inhibition was completely blocked by propranolol (0.5 mug/ml). 6 The results indicate the presence of an inhibitory beta-adrenoceptor and suggest the possibility of an excitatory alpha-adrenoceptor in guinea-pig urinary bladder.  (+info)

Fingerprint Dive into the research topics of Effects of cardiac rehabilitation and beta-blocker therapy on heart rate variability after first acute myocardial infarction. Together they form a unique fingerprint. ...
There was also no difference in the incidence of the primary endpoint among patients with CAD without a history of MI (12.94 percent vs. 13.55 percent, respectively; p = 0.31). In the cohort of patients only with CAD risk factors, the primary endpoint occurred more frequently among those taking beta-blockers (14.22 percent vs. 12.11 percent, p = 0.02).. Among patients enrolled in the international REACH registry, beta-blocker use was not associated with a lower event rate of cardiovascular events at 44-month follow-up, even among patients with prior history of MI, the study authors concluded. They suggest further research is warranted to identify subgroups that benefit from beta-blocker therapy and the optimal duration of beta-blocker therapy.. ...
Overall 25,517 (46.4%) patients in the study sample were prescribed beta-blockers at discharge. The rate of beta-blocker use declined as COPD or asthma severity increased (p , 0.001). Beta-blockers were prescribed for 50.3% of patients without COPD or asthma, 37.4% of patients with COPD or asthma not prescribed beta-agonists, 25.2% of patients with COPD or asthma prescribed beta-agonists, and 12.5% of patients with severe COPD or asthma. Over 91% of patients discharged on beta-blockers were prescribed beta1-selective agents. After adjusting for demographic and clinical factors, patients with COPD or asthma continued to be less likely to be prescribed beta-blocker therapy compared with patients without pulmonary disease (odds ratio [OR] 0.65) (95% confidence interval [CI] 0.62 to 0.69, for patients with COPD or asthma not prescribed beta-agonists, OR 0.38 [95% CI 0.34 to 0.41] for patients with COPD or asthma prescribed beta-agonists but not prescribed oral steroids or admitted in the prior year, ...
Eesti Teadusinfosüsteem koondab informatsiooni teadus- ja arendusasutuste, teadlaste, teadusprojektide ning erinevate teadustegevuste tulemuste kohta.
Postsystolic shortening (PSS), a positive myocardial velocity after aortic valve closure as assessed by tissue Doppler imaging (TDI), is a common finding in patients with myocardial disease. Beta-blocker therapy is shown to improve both global and regional myocardial function. The aim of the present study was to examine whether beta-blocker therapy might reduce incidence and magnitude of PSS in patients with nonischemic dilated cardiomyopathy. Before and a few months after beta-blocker (carvedilol) therapy, 19 patients (7 men and 12 women, age 59±13 years) underwent conventional echo-assessment and TDI. From the apical two, four, and long-axis views, we constructed time velocity curves at the 12 basal and mid-myocardial segments of the left ventricular (LV) walls. PSS was defined if the positive myocardial velocity after aortic valve closure was greater than the ejection peak (Figure⇓). The number of PSS was counted before and after beta-blocker therapy. Beta-blocker therapy decreased LV ...
A recent study by Australian researchers suggests that cardiovascular medications known as beta-blockers can decrease the risk of osteoporosis-related bone fractures by half.
Source: Can you eat bananas with beta-blockers? At certain times, yes, you can eat bananas even when taking beta-blockers. However, too much potassium can lead to kidney failure and inconsistent heart rhythm. Thus, your doctor may advise and recommend that you restrict your consumption of bananas if you are taking a beta-blocker. The limitation goes with other high-potassium foods, including tomato, papaya, kale, and avocado.. How long can you stay on beta-blockers? Propranolol is usually taken short-term for anxiety medication. That is because its main purpose is to help with physical symptoms. It reduces heart rate and blood pressure, which improves blood flow and eases the workload on your heart. Though there has never been an issue with taking it for too long, you still need to consult your doctor about the risks and benefits of taking it for an extended period. Remember, its best to take the beta blocker only for as long as you need it.. What are the long-term side effects of ...
Dive into the research topics of Current role of beta-adrenergic blockers in the management of chronic heart failure. Together they form a unique fingerprint. ...
The percentage of patients 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who were prescribed persistent beta-blocker treatment for six months after discharge
The main finding of the present meta-analysis indicates that the effect of beta-blockers in patients with HF and AF is significantly different from the effect of these drugs in patients with HF and sinus rhythm. Indeed, beta-blockers were not found to have a favorable effect on HF hospitalizations or mortality in 1,677 AF patients who had been enrolled in placebo-controlled, randomized studies.. This finding is important as most patients with HF and AF receive beta-blocker treatment. Beta-blockade is recommended in the current guidelines for HF and AF treatment, albeit for different indications (1,23). In HF treatment guidelines, beta-blockers are recommended for all patients in order to reduce morbidity and mortality, without differentiation regarding rhythm. As such, these drugs are part of the standard medical therapy for all patients with HF and reduced LVEF. In addition, beta-blocker therapy has been shown to prevent new onset or recurrent AF in patients with HF (15,24) after myocardial ...
This analysis demonstrates that trial results of beta-blocker therapy in patients with CHF are consistent with a beneficial effect on total and cardiovascular mortality. The overall decrease in the odds of death was 31%, with one death prevented per 35 patients treated. The benefit from beta-blockade was consistent over the studies examined; however, it was most pronounced in the studies of carvedilol, which account for 55% of all included patients.. Previous studies, including a meta-analysis ([21]), have demonstrated that beta-blockade can improve left ventricular ejection fraction, symptoms and morbidity indices ([14-20]). The finding of improved mortality with beta-blockade has also been suggested by many previous studies, but most have lacked the statistical power to find even moderate improvements in survival ([14, 15, 17, 18, 33, 38, 42-44, 49, 56]). The results from this meta-analysis increase confidence in the hypothesis that beta-blockade reduces mortality in heart failure.. Previous ...
According to the reports from Ministry of Health in each country, the average life spans were expanded over the past century. This trend is expected to be extended furt..
Andrews et al performed the first meta-analysis in this area. They found that 13 of 19 studies investigating the benefit of prophylactic beta-blockers showed a significant benefit in favour of giving prophylaxis. Pooling all these results showed a reduction in AF from 34% to 8.7% from studies involving 1,549 patients. Interestingly no difference was shown when pre-operative beta-blocker studies were compared to post-operative studies. No benefit was shown in 8 studies assessing either verapamil or digoxin as AF prophylaxis. They also showed that the mean ventricular rate was significantly lower in beta-blocked patients when they did go into AF, with a mean rate 24bpm slower than controls. They did caution that most patients in these studies were young, male and had good ejection fractions and had been on beta-blockers pre-operatively. Kowey et al in 1992 pooled data from 7 studies containing 1,418 patients, and found a reduction in AF from 20% to 9.8%. In addition they pooled data from 2 studies ...
Aims: We sought to: (1) estimate the proportion of patients who initiated beta-blocker therapy after acute myocardial infarction (AMI) in Regione Emilia-Romagna (RER); (2) examine predictors of post-AMI beta-blocker initiation; and (3) assess adherence to such therapy. Methods and Results: Using healthcare claims data covering all of RER, we identified a cohort of 24,367 patients with a hospitalization for AMI between 2004 and 2007, who were discharged from the hospital alive and without contraindications to beta-blocker therapy. We estimated the proportion of eligible patients with at least one prescription for a beta-blocker following discharge and performed a multivariable logistic regression analysis to identify independent predictors of post-AMI beta-blocker initiation. We computed the proportion of days covered (PCD) as a measure of medication adherence at 6 and 12 months post-discharge. Following discharge, 16,383 (67%) cohort members initiated beta-blocker therapy. Independent predictors of beta
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Ivabradine acts by selectively inhibiting the
MONDAY, July 13, 2020 (HealthDay News) -- Millions of Americans are prescribed blood pressure medicines called beta blockers, especially after a heart attack. But a new Italian study finds that these go-to drugs might not work as well for women as they do for men.. What we found presents a solid case for reexamination of the use of beta blocker therapy for women with hypertension, said study lead author Dr. Raffaele Bugiardini, professor of cardiology at the University of Bologna.. The study couldnt prove a cause-and-effect link, but among patients taking beta blockers, women had a 4.6% higher rate of heart failure than men when going to the hospital with a heart attack or chest pain (angina), the study found.. For women who have no history of cardiovascular disease and only hypertension, we think it is incredibly important for them to regulate their blood pressure through diet and exercise [first], Bugiardini said in a news release from the journal Hypertension. His team published the ...
Beta-blockers, a type of drug frequently prescribed for people with heart disease, may not reduce the risk of a second heart attack, death, or stroke in people with coronary artery disease (CAD). In people with risk factors for heart disease, beta-blockers may increase the risk of such events, according to findings from a recent large observational study conducted by a team of investigators from the Cardiac and Vascular Institute at NYU Langone Medical Center.
This study addressed the question of when and in whom TNF blocker drugs can be stopped. Guidelines are available on when to start TNF blocker therapy and how to induce remission,18 but there is little information regarding patient management once remission is achieved. For most patients, current practice is to continue treatment indefinitely and to stop only for adverse events or secondary non-response. This study assessed clinical, imaging and immunological measures to establish what happens when successful cessation of TNF blockade therapy is achieved. Importantly, our data are the first to show that successful cessation of TNF blocker therapy is more likely if combination therapy is used as first-line treatment. The low levels of inflammation on ultrasound in these patients provided insufficient variance to be associated with outcome. Immunological findings strongly suggest that a state of immunological suppression of inflammation could be associated with sustained remission when patients ...
Beta Blockers - MedHelps Beta Blockers Center for Information, Symptoms, Resources, Treatments and Tools for Beta Blockers. Find Beta Blockers information, treatments for Beta Blockers and Beta Blockers symptoms.
And in a separate look at 30 patients with high blood pressure, they found that people on beta-blockers generally burned fewer calories and fat after a meal - measured by a device called a calorimeter. The patients on beta blockers also reported lower physical activity levels in their day-to-day lives ...
20 double-blind RCTs evaluated the BP lowering efficacy of beta-blockers as second-line drug in 3744 hypertensive patients (baseline BP of 158/102 mmHg; mean duration of 7 weeks). The BP reduction from adding a beta-blocker as the second drug was estimated by comparing the difference in BP reduction between the combination and monotherapy groups. A reduction in BP was seen with adding a beta-blocker to thiazide diuretics or calcium channel blockers at doses as low as 0.25 times the manufacturers recommended starting dose. The BP lowering efficacy of beta-blockers as a second drug was 6/4 mmHg at 1 times the starting dose and 8/6 mmHg at 2 times the starting dose. Beta-blockers reduced heart rate by 10 beats/min at 1 to 2 times the starting dose. Beta-blockers did not statistically significantly increase withdrawals due to adverse effects but this was likely due to the lack of reporting of this outcome in 35% of the included RCTs.. ...
Synonyms for beta-adrenergic blocking agent in Free Thesaurus. Antonyms for beta-adrenergic blocking agent. 3 synonyms for beta-adrenergic blocking agent: beta blocker, beta-adrenergic blocker, beta-blocking agent. What are synonyms for beta-adrenergic blocking agent?
Between June 2004 and April 2008, 497 statin-naive patients scheduled for vascular surgery were included in the trial at Erasmus MC Rotterdam, The Netherlands. Patients were randomised to receive either placebo or fluvastatin extended release at a dose of 80mg once daily. Treatment was started at the outpatient clinic on the day of randomisation, median 37 days prior to the surgical procedure and was continued at least during the first 30 days after surgery. Inflammatory markers at baseline, including hs-CRP and IL-6 were assessed in patients allocated to fluvastatin or placebo. At hospital, admission levels of hs-CRP and IL-6 were significantly lower in patients on fluvastatin (respectively 6mg/L vs. 4.66mg/L, p=.030 and 8.45pg/mL vs 5.75pg/mL, p=.024). The primary analysis was intention-to-treat and involved all patients who were randomly assigned to either fluvastatin or placebo. Directly after surgery, study treatment was temporarily discontinued in 115 (23%) patients for a median duration ...
Methods and Results-The study included 5926 consecutive patients who underwent CABG and were discharged alive. The prevalence and consistency of β-blocker use were determined in patients with and without a history of myocardial infarction (MI). β-Blockers were always used in 1280 patients (50.9%) with and 1642 patients (48.1%) without previous MI after CABG. Compared with always users (n=2922, 49.3%), the risk of all-cause death was significantly higher among inconsistent β-blocker users (hazard ratio [HR], 1.96; 95% confidence interval [CI], 1.50-2.57), and never using β-blockers was associated with increased risk of both all-cause death (HR, 1.42; 95% CI, 1.01-2.00) and the composite of adverse cardiovascular events (HR, 1.29; 95% CI, 1.10-1.50). In the cohort without MI, the HR for all-cause death was 1.70 (95% CI, 1.17-2.48) in inconsistent users and 1.23 (95% CI, 0.76-1.99) in never users. In the MI cohort, mortality was higher for inconsistent users (HR, 2.14; 95% CI, 1.43-3.20) and ...
The Aim is to define the contribution of genetic variation to the interindividual variability in response to β-blockade. The rationale for the study is as follows: Beta-blockers prevent the activation of β-ARs and thus form the cornerstone of treatment of pathological states such as congestive heart failure and coronary artery disease. Functional polymorphisms in cardiac beta-receptors have been shown to determine response to β-blocker therapy. A physiologic stimulus such as exercise causes sympathetic stimulation and activation of the cardiac β-ARs and genotypic differences in response to β-blockers are magnified under states of heightened sympathetic activity. Thus, in addition to measuring the response to β-blockers at rest, we will also determine the response to β-blockade after sub-maximal exercise on a supine bicycle ergometer. Genetic variations that may alter sensitivity to a beta blocker will be sought ...
Learn more about Beta-blockers at Reston Hospital Center Coenzyme Q 10 (CoQ 10 ) -Supplementation....
Learn more about Beta-blockers at Doctors Hospital of Augusta Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Doctors Hospital of Augusta Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Portsmouth Regional Hospital Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Memorial Hospital Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Oak Hill Hospital Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Memorial Hospital Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Regional Medical Center Bayonet Point Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Wesley Medical Center Coenzyme Q 10 (CoQ 10 ) -Supplementation.....
Learn more about Beta-blockers at Largo Medical Center Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Orange Park Medical Center Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Learn more about Beta-blockers at Regional Medical Center Bayonet Point Coenzyme Q 10 (CoQ 10 ) -Supplementation...
Assumption: Precaution is needed when taking any medication during pregnancy. Beta-blockers for high blood pressure are included. TRUE Although beta-blockers taken during pregnancy can help lower blood pressure, babies whose mothers took beta-blockers grew more slowly than average babies. My Views: Of course, your care provider must help you weigh the benefits and risks…
This was a retrospective study, which means the data for it came from previously treated patients, but it was reasonably large (722 patients, of whom 155 were taking beta blockers). So, while this is solid evidence its not the same as a randomised clinical trial. There are lots of questions still to be explored, for example does the effect of beta blockers depend on prior exposure (i.e. do you have to have been taken them for a long time before diagnosis), is the effect still there if beta blockers are started after diagnosis, and at what dosage ...
First, before I forget, extreme nausea can be a symptom that heart failure is worsening. Personally, though, Id expect it to become progressively worse, not to come rampaging out of nowhere the way it did - I still suspect Nebivolol was the culprit. I will, however, bear it in mind and keep a close eye…
A new meta-analysis, one that excludes the largely discredited DECREASE studies conducted by disgraced researcher Dr Don Poldermans, suggests that beta-blocker use during noncardiac surgery is killing patients.
Ive been taking beta-blockers, propranolol and then atenolol, for palpitations for years. They dont make me dizzy, and don...
Limitations of the study included the lack of patients with milder forms of COPD airflow obstruction or exacerbation risk, and of course, the trials early end limiting the outcomes. Additionally, investigators had not enrolled patients with a proven indication of beta-blocker use or a prior history with the drug ...
The CSM has advised that beta-blockers, including those considered to be cardioselective, should not be given to patients with a history of asthma or bronchospasm. However, in rare situations where there is no alternative a cardioselective beta-blocker may be used with extreme caution under specialist supervision. Combination preparations containing a beta-blocker are not recommended as they lack flexibility and may not be available in dose combinations appropriate for individual patients ...
A new study adds to doubts about using beta blockers to reduce the risks of surgery. The death rate for people given beta blockers before non-cardiac surgery wa
Beta blockers are used to treat certain types of heart-related problems. Learn about the benefits of using beta blockers from Discovery Health.
Beta blockers are great for treating anxiety and heart conditions, but there are things you should know before you consider trying them.
Nebivolol, (bystolic, nebilet, nebil) is a long acting cardioselective beta-blocker at present approved for the therapy of high blood pressure. Nebivolol is
What are beta-blockers? How do they work? What are they used to treat? These are the kinds of question we answer in todays article; your complete guide!
Beta-adrenergic receptor blockers have been studied for minimizing the effects of catecholamines by blocking their activation of beta receptors. They are used to prevent or treat hypertensive crises, tachycardia, ischemic cardiomyopathy, and arrhythmias. Several studies have shown the efficacy of such drugs in decreasing postoperative morbidity and mortality. This study aimed to evaluate the benefit of perioperative beta-blocker therapy in improving the outcome of CABG surgery regarding intra- and postoperative arrhythmias and ventricular function. It was a prospective controlled nonrandomized study conducted on 50 patients undergoing elective CABG in Ain Shams University hospitals, in which the study group, who were the patients who were compliant on beta-blocker therapy, received 1 mg of propranolol before removal of aortic cross clamp and continued on beta-blocker therapy in the postoperative period, while the control group who were not on beta-blocker therapy received an equivalent volume of normal
Tab metoprolol xl 50 mg, metoprolol mechanism of action slideshare, metoprolol package insert fda, metoprolol succinate brand name in india, metoprolol succinate and anxiety, metoprolol succinate and naproxen, metoprolol succinate er 50 mg cost
Metoprolol tartrate and turmeric, photo metoprolol succinate, metoprolol succinate 50 mg goodrx, metoprolol succinate xl 25 mg tablet, para que sirve el metoprolol tartrate 25 mg
Objectives The purpose of this study was to compare the efficacy of beta-blockers in congenital long QT syndrome (LQTS). Background Beta-blockers are the mainstay in managing LQTS. Studies comparing the efficacy of commonly used beta-blockers are lacking, and clinicians generally assume they are equally effective.. Methods Electrocardiographic and clinical parameters of 382 LQT1/LQT2 patients initiated on propranolol (n = 134), metoprolol (n = 147), and nadolol (n = 101) were analyzed, excluding patients ,1 year of age at beta-blocker initiation. Symptoms before therapy and the first breakthrough cardiac events (BCEs) were documented.. Results Patients (56% female, 27% symptomatic, heart rate 76 +/- 16 beats/min, QTc 472 +/- 46 ms) were started on beta-blocker therapy at a median age of 14 years (interquartile range: 8 to 32 years). The QTc shortening with propranolol was significantly greater than with other beta-blockers in the total cohort and in the subset with QTc ,480 ms. None of the ...
Looking for online definition of Adrenergic beta-antagonists in the Medical Dictionary? Adrenergic beta-antagonists explanation free. What is Adrenergic beta-antagonists? Meaning of Adrenergic beta-antagonists medical term. What does Adrenergic beta-antagonists mean?
Tags:. what does metoprolol xl look like metoprolol tartrate iv to po conversion alternative drugs for metoprolol tartrate metoprolol and furosemide what is a natural diuretic lopressor side effects elderly cardiac effects of metoprolol classification of metoprolol succinate can metoprolol cause tremors metoprolol dosage for tachycardia antidote metoprolol lexapro lopressor metoprolol cr blood pressure metoprolol confusion side effects hair loss metoprolol treatment metoprolol tartrate and muscle weakness lopressor therapeutic action metoprolol retard halbwertszeit metoprolol allergy cross reactivity metoprolol tartrate for sinus tachycardia nursing implications for metoprolol succinate side effects of metoprolol succinate er bisoprolol gleich metoprolol metoprolol succinate patent litigation excedrin migraine and metoprolol diuretic diet what dosage of metoprolol for anxiety myasthenia gravis metoprolol metoprolol dosage atrial fibrillation leeks diuretic metoprolol succinate adderall ...
Purified sarcolemmal and light vesicle (intracellular) fractions of beta-adrenergic receptors were used to examine the effects of propranolol on receptor translocation in guinea pig heart. Guinea pigs were given propranolol (0.15 mg/kg/hr) via minipumps for 7 days and either killed or made ischemic for 1 hour via a coronary ligature. Propranolol treatment led to an externalization of beta-receptors from light vesicle to sarcolemmal fractions. This externalization increased the number of surface beta-adrenergic receptors that were functional, as assessed by isoproterenol-stimulated adenylate cyclase activity. After chronic propranolol treatment, ischemia did not further alter receptor distribution. These results suggest that externalization of beta-adrenergic receptors from a light vesicle fraction to the sarcolemma contributes to up-regulation of beta-receptors that occur in response to both propranolol treatment and ischemia. Because propranolol-treated animals show blunting in externalization ...
Toprol xl conversion to metoprolol succinate. Carvedilol versus metoprolol. What is the drug toprol used for. Fatal overdose of metoprolol. Diabetes metoprolol. Asthma metoprolol. Atenolol metoprolol comparison essay. Lamictal and herbal interactions with metoprolol. Altace aspirin interaction with metoprolol. Teva metoprolol 100 mg. Nebivolol versus metoprolol. Rxlist metoprolol side. Metoprolol side effects lopressor. Metoprolol 100mg xr. Metoprolol er 50 mg side effects. High blood pressure toprol. Toprol e cig. Metoprolol maximum dosage. Sotalol and metoprolol combination lock. Metoprolol and slow pulse. Clozaril nursing considerations for metoprolol. Metoprolol 50mg er recall. What does toprol xl 25 mg look like, Bystolic vs toprol xl 100, Metoprolol succinate 50 mg tablet, Metoprolol succ er 100 mg coupons, Metoprolol succinate drug classification, Metoprolol tartrate succinate comparison quotes, Stopping metoprolol safely, Metoprolol pill identification, Metoprolol succ er 50 mg tab ...
Fingerprint Dive into the research topics of Effect of beta-blocker therapy on heart rate response in patients with hypertension and newly diagnosed untreated obstructive sleep apnea syndrome. Together they form a unique fingerprint. ...
Convert coreg to metoprolol, tartarato de metoprolol 50mg referencia, metoprolol pictures, metoprolol tartrate oral use, amlodipine besylate and metoprolol succinate, metoprolol succinate er 24hr 50 mg tab, metoprolol 50 mg tab
Metronidazole iv to po conversion metoprolol, Metoprolol succinate nursing considerations, Metoprolol nursing responsibilities for resume, Toprol xl splitting bee, Felodipine and metoprolol, Metoprolol er tab 50mg, Metoprolol how long to work, Dilantin iv to po conversion metoprolol, Metoprolol succinate metabolism, Metoprolol 5 mg tablets, Metoprolol tartrate 50 mg tabs, Metoprolol tartrate dosage forms preparation, Clonidine and metoprolol, Atenolol and metoprolol taken together, Metoprolol succinate 25 mg price, Metoprolol lethal dose of morphine, Metoprolol 50 mg tab teva, Toprol xl patent, Metoprolol side effects in men, Buy toprol xl 25mg online. Xanax and metoprolol, Can amlodipine and metoprolol be taken together, How does metoprolol cause weight gain, Toprol shortage, Phenytoin interaction xanax and metoprolol, How to taper off metoprolol succinate 25mg, Metoprolol and atenolol dosages, Metoprolol and kidney problems, Metoprolol succinate insomnia, Metoprolol manufacturer coupon, ...
Metoprolol succinate safe for breastfeeding, metoprolol er 831, atenolol metoprolol equivalent, carvedilol equivalent to metoprolol, metoprolol to carvedilol conversion chart, metoprolol tartrate 25mg c73, metoprolol succinate extended release
Que es metoprolol succinate, atenolol po to metoprolol iv conversion, metoprolol succinate er 50 mg tb24, metoprolol interactions ibuprofen, metoprolol 100 mg cena, metoprolol wikipedia english, para que sirve el metoprolol tartrate 50
Toprol xl prescribing information, buy cheap metoprolol tartrate, metoprolol succinate extended release half life, side effects of metoprolol succinate 100 mg, metoprolol tartrate 50mg tablets side effects, converting lopressor to toprol xl, metoprolol tartrate food interactions
Metoprolol succinate er 25 mg coupons, metoprolol succinate er 50 mg pill identifier, metoprolol 50 mg patente, metoprolol de 50 mg pret, metoprolol xl cost, metoprolol ratiopharm succinat 47 5 mg retardtabletten
Generic version of metoprolol succinate, toprol xl metoprolol, metoprolol succinate generic price, metoprolol lopressor 25mg, lopressor hct, is metoprolol a generic for toprol xl, lopressor 100 mg pictures
Adrenergic beta-blocking agents were given to 7 patients with advanced congestive cardiomyopathy who had tachycardia at rest (98 plus or minus 13 beats/min). The patients were on beta-adrenergic receptor blockade for 2 to 12 months (average 5-4 months). One patient was given alprenolol 50 mg twice daily and the other patients were given practolol 50 to 400 mg twice daily. Virus infection had occurred in 6 of the patients before the onset of symptoms of cardiac disease. All patients were in a steady state or were progressively deteriorating at the start of beta-adrenergic receptor blockade. Conventional treatment with digitalis and diuretics was unaltered or reduced during treatment with beta-blocking agents. An improvement was seen in their clinical condition shortly after administration of the drugs. Continued treatment resulted in an increase in physical working capacity and a reduction of heart size. Noninvasive investigations including phonocardiogram, carotid pulse curve, apex cardiogram, ...
Beta blockers have been proven to have benefit in heart failure (HF) patients with regard to morbidity and mortality. However, initiation and uptitration remains a challenge in many patients. Worsening of heart failure, symptomatic hypotension and symptomatic bradycardia all limit up-titration to the target doses that have been shown to have mortality benefits (carvedilol [Coreg] 25 mg bid, metoprolol succinate [Toprol-XL] 200 mg qd) in the large clinical trials (COPERNICUS, MERIT-HF).. It is debated whether the benefit of beta-blockade is solely due to heart rate reduction or more broadly from the cardiac, central and peripheral effects of blocking sympathetic activity. Clearly, there is a remodeling effect on the dilated ventricle. Furthermore, patients with heart rates of 64 bpm or less are rarely begun on beta-blocker therapy. It is not known whether these patients should be given a pacemaker in order to then safely initiate beta-blocker therapy.. It is also clear that isolated right ...
Metoprolol tartrate 25 mg twice a day side effects, apo metoprolol and exercise, metoprolol drug interactions warnings, metoprolol succinate 100 mg sa tab, metoprolol mims ph, metoprolol tartrate po to iv conversion, metoprolol toprol xl
Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation. Am J Physiol Heart Circ Physiol 293: H1596-H1603, 2007. First published June 8, 2007; doi:10.1152/ajpheart.00308.2007.- Cardiac beta-adrenergic receptor (*-AR) signaling and left ventricular (LV) responses to beta-AR stimulation are impaired with aging. It is shown that exercise and beta-AR blockade have a favorable effect on cardiac and vascular *-AR signaling in several cardiovascular diseases. In the present study, we examined the effects of these two different strategies on *-AR dysregulation and LV inotropic reserve in the aging heart. Forty male Wistar-Kyoto aged rats were randomized to sedentary, exercise (12 wk treadmill training), metoprolol (250 mg kg-1 day-1 for 4 wk), and exercise plus metoprolol treatment protocols. Ten male Wistar- Kyoto sedentary young rats were also used as a control group. Old ...
Metoprolol in hypertension. What is metoprolol succ er taken for. Toprol strength. Metformin and herbal interactions with metoprolol. Metoprolol er 25mg side effects. Stop taking toprol xl. Altace and toprol xl and weight. Toprol side effect cough. Cipro iv to po conversion metoprolol. Metoprolol tartrate 25 mg pill picture. Nebivolol to metoprolol conversion. Blood pressure medication toprol. Amlodipine metoprolol combination. Anxiety metoprolol. Metoprolol succinate dosages available. Inderal nursing considerations for metoprolol. Adalat atenolol vs metoprolol. Metoprolol erowid adderall. Toprol xl uses. Toprol xl vs metoprolol succ er. What does toprol xl 25 mg look like. Toprol online. Metoprolol terbinafine interaction. Solu medrol iv push rate for metoprolol. Bystolic vs metoprolol succinate. Metoprolol succinate er tab 25 mg, Lexapro and metoprolol, Metoprolol tartrate 25 mg mylan, Metoprolol stomach gas, Metoprolol and bladder problems, Metoprolol succinate used for anxiety, Toprol xl ...
PD-Rx Pharmaceuticals, Inc.: Metoprolol succinate extended-release tablets is a beta 1 -selevitve adrenoceptor blocking agent. Metoprolol succinate...
Physician reviewed Metoprolol Succinate ER patient information - includes Metoprolol Succinate ER description, dosage and directions.
Find here online price details of Olmesartan (20mg) + Metoprolol Succinate (50mg) Brands in India. Order all generics/substitutes of Olmesartan (20mg) + Metoprolol Succinate (50mg) at Low Prices Guaranteed.
What does metoprolol succinate do cialis 10 mg cryptocurrency 10 pills in a package only 12 USD. Pill identifier metoprolol succinate inexpensive.
Metoprolol er succinate 50 mg half life, metoprolol webmd, metoprolol ratiopharm 23 75 mg, metoprolol succinate dose, metoprolol pret, convert atenolol to metoprolol xl, para que sirven las pastillas metoprolol metoprolol
Metoprolol side effects rash pictures, what is metoprolol er used for, what does the pill metoprolol tartrate look like, is metoprolol safe in pregnancy, metoprolol tartrate vs metoprolol xl, nipresol metoprolol para que sirve, metoprolol mechanism of action
Metoprolol 200 mg bid, metoprolol tartrate side effects, para que sirve nipresol metoprolol 100 mg, metoprolol succinate 25 mg xl, metoprolol 75 mg cost
Metoprolol 25 mg krka, metoprolol succ er 25 mg tab tablet extended release, para que se usa el metoprolol tartrate 50 mg, transition metoprolol tartrate to succinate conversion, teva-metoprolol (rose) 50 mg, metoprolol succ er 25 mg tab tablet extended, picture of metoprolol succinate er
Metoprolol iv to po calculator, metoprolol tartrate and advil, metoprolol tartrate xl half life, metoprolol betaloc zok, conversion carvedilol to metoprolol, buy metoprolol-tartrate, metoprolol succinate uses and side effects
Drug Information on Lopressor, Metoprolol Succinate ER, Metoprolol Tartrate (metoprolol) includes side effects, uses, drug interactions, dosage, drug pictures, overdose symptoms, and what to avoid.
Metoprolol tartrate xl half life, what is apo-metoprolol used for, generic metoprolol, metoprolol succinate 50 mg picture, metoprolol to carvedilol conversion chart, toprol xl and metoprolol difference, metoprolol wikipedia english
Metoprolol fiyat, metoprolol succinate generic manufacturers, metoprolol and betaloc zok, beta blocker conversion metoprolol to bisoprolol, metoprolol tartrate neobloc
Metoprololsuccinat 47 5 mg wofr, metoprolol for afib dose acls, metoprolol 47 5 mg wirkungsdauer, metoprolol tartrate for migraines, metoprolol 25 tab, what does generic toprol xl look like, cost of metoprolol succinate er
Metoprolol succinate er 25 mg best time to take, metoprolol xl 25 mg side effects, metoprolol tartrate 25 mg twice a day reviews, metoprolol succ er 25 mg tab tablet extended release, metoprolol sandoz 50 mg pris, bnf online metoprolol
Get information, facts, and pictures about Adrenergic beta-antagonists at Make research projects and school reports about Adrenergic beta-antagonists easy with credible articles from our FREE, online encyclopedia and dictionary.
What is metoprolol side effects, metoprololtartraat, metoprolol succinate 50 mg goodrx, metoprolol succ er 25 mg tablets, metoprolol 6.25 mg, what is metoprolol look like, metoprolol dosage for svt
Metoprolol succinate half life, metoprolol xr side effects, metoprolol er half life, metoprolol pill identifier, metoprolol er succinate 25 mg reviews, metoprolol coupon, metoprololsuccinat wiki
A non-selective beta-adrenergic antagonist … A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. (PubChem) Pharmacology: Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. Mechanism of action: Like ...
What does metoprolol succinate 50 mg look like, metoprolol actavis 25 mg, metoprolol 100 mg mexico, metoprolol tartrate 50 mg cost walmart
Buy metoprolol succinate er, metoprolol atenolol equivalent dose, generic toprol xl recall, metoprolol tartrate to atenolol conversion, toprol generic pictures, toprol xl 25 mg tablet generic, toprol xl beta blocker
One other option is the use of metoprolol succinate, which is known as a beta blocker. These are very common when used to treat both hypertension and cardiac ischemia. They work by limiting the bodys ability to produce epinephrine, which is basically just adrenaline. Many people are familiar with the way that adrenaline works from sports or stressful situations, in which it can flood the body with energy. This also causes the persons heart to beat quickly or to beat harder, both of which can increase blood pressure. To a smaller degree, epinephrine is always doing this, even when there is no notable increase due to outside stimuli.. The beta blockers lower the production levels without stopping them completely, and so less epinephrine means that the heart does not work as aggressively. It slows down, pumping less blood and working less vigorously to do so. This takes a lot of pressure off of the artery walls, therefore reducing the risk of issues like cardiac ischemia, stroke, and the like. ...
Comparative Effects of Preoperative Angiotensin-converting Enzyme In-hibitor, Statin and Beta-blocker Treatment on Human Internal Mammary Artery Reactivity in Patients with Coronary Artery Disease: A Pilot Study
Metoprolol er succinate 25mg - plans, specifications, and estimates, advertising, and award procedures are to be followed when a std.
Metoprolol Succinate is the name of the medication. It comes in the form of a tablet, and should be taken by mouth. It belongs to a class of medications called Beta Blocker.
Metoprolol Succinate is the name of the medication. It comes in the form of a tablet, and should be taken by mouth. It belongs to a class of medications called Beta Blocker.
... is a beta-adrenergic antagonist. Nakayama, K; Oshima, T; Koike, H (1981). "Assessment of beta-blockade and the non- ... a beta-adrenergic blocking agent, on atrioventricular conduction in anesthetized dogs". Archives Internationales de ...
... is a beta-adrenergic antagonist. Cheymol, G; Jaillon, P; Lecoq, B; Lecoq, V; Cheymol, A; Krumenacker, M (1987). " ... "Cardiovascular beta-adrenergic blocking effects of bornaprolol in humans: Relation to dose and plasma concentration". Journal ...
... is a beta-adrenergic antagonist.[1] References[edit]. *^ Haddad, S; Poulin, P; Funk, C (2010). "Extrapolating in ...
... is a beta adrenergic receptor antagonist. Stache, U; Fritsch, W; Fehlhaber, HW (1987). "Synthesis of the highly ... cardioselective beta-sympatholytic pacrinolol". Arzneimittel-Forschung. 37 (11): 1217-21. PMID 2894210. v t e v t e. ...
... is an antiarrhythmic beta adrenergic antagonist. Koytchev, R; Alken, RG; Mayer, O; Smith, I; Greenwood, M (1996). " ...
... is a beta adrenergic receptor antagonist. Lombardi, F; Terranova, P (2006). "Pharmacological treatment of atrial ...
... is a beta adrenergic receptor antagonist. Mostaghim, R; Maddox, YT; Ramwell, PW (1986). "Endothelial potentiation ... of relaxation response to beta adrenoceptor blocking agents". The Journal of Pharmacology and Experimental Therapeutics. 239 (3 ...
Beta-adrenergic antagonists may also interact with sympathomimetics. Increase of ectopic pacemaker activity can occur when ... α-Adrenergic receptors are located on the muscles lining the walls of blood vessels. When these receptors are activated, the ... Activation of β2-adrenergic receptors produces relaxation of smooth muscle of the bronchi, causing bronchial dilation and in ... Its principal mechanism of action relies on its direct action on the adrenergic receptor system. The vasoconstriction that ...
... seems to have beta-adrenergic antagonist properties. Flower closeup Flower closeup Naples garlic (Allium ...
... is a beta-adrenergic antagonist. Halabi, A; Endell, W; Halabi, I; Kirch, W (1990). "Hemodynamic effects of ...
Beta blocker Adrenergic antagonist Katzung, Bertram. Basic and Clinical Pharmacology. Katzung, Bertram; Masters, Susan (2013). ... Non-selective α-adrenergic receptor antagonists include: Phenoxybenzamine Phentolamine Tolazoline Trazodone Selective α1- ... are a class of pharmacological agents that act as antagonists on α-adrenergic receptors (α-adrenoceptors). Historically, alpha- ... adrenergic receptor antagonists include: Alfuzosin Doxazosin Prazosin (inverse agonist) Tamsulosin Terazosin Silodosin ...
J. W. Black; A. F. Crowther; R. G. Shanks; A. C. Dornhorst (1964). "A new adrenergic beta-receptor antagonist". The Lancet. 283 ... as either alpha or beta adrenergic blocking drugs." Dichloroisoprenaline was the first beta blocker; it retains some intrinsic ... that both are beta type receptors. … It is suggested that this terminology be extended to the realm of adrenergic blocking ... he called beta adrenotropic receptor (now β-adrenoceptor or β-adrenergic receptor). ″This concept of two fundamental types of ...
... is a beta adrenergic antagonist. It is the (S)-enantiomer of moprolol. Gianesello, V; Brenn, E; Figini, G; ... Gazzaniga, A (1989). "Determination by coupled high-performance liquid chromatography-gas chromatography of the beta-blocker ...
Adverse experience with cimetidine and safety of beta-adrenergic antagonists". Arch Intern Med. 145 (12): 2197-200. doi:10.1001 ... Previously, beta blockers have been assumed as risk factor for the acquisition of contrast medium-induced adverse reactions/ ... Due to recent investigations it became clear that beta blockers do not increase the frequency of adverse reactions in concert ... Boehm I, Morelli J, Nairz K, Silva Hasembank Keller P, Heverhagen JT (2016). "Beta blockers and intravenous roentgen contrast ...
... is a beta adrenergic receptor antagonist. Curtis-Prior, PB; Gadd, AL (1990). "Beta-adrenoceptor antagonists and human ...
... is a beta adrenergic receptor antagonist. Lennernäs, H; Regårdh, CG (1993). "Dose-dependent intestinal absorption and ... significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat". Pharmaceutical Research. 10 (5): 727- ...
... is a beta adrenergic receptor antagonist. Mahé, N; Do, B; Nicolaï, B; Rietveld, IB; Barrio, M; Tamarit, JL; Céolin, ...
... is a beta adrenergic receptor antagonist. The methyl group on a sulfoxide is sufficiently acidic to substitute for ... "Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists". J. ...
... is a beta adrenergic receptor antagonist. Allen, JD; Shanks, RG (1974). "Effects of tiprenolol, practolol and ...
... is a beta adrenergic receptor antagonist. Mannucci, C; Caviglioli, G; Perico, A; Triolo, A (1992). "High-performance ...
... is a beta adrenergic receptor antagonist. Stephenson, KA; Wilson, AA; Meyer, JH; Houle, S; Vasdev, N (2008). "Facile ... radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of 18F-(2S and 2R)-1 ...
... is a beta adrenergic receptor antagonist. Gries, J; Unger, L; Einig, H; Friedrich, L; Hofmann, HP; Kreiskott, H; ... "Pharmacological characterization of the new highly potent beta-adrenergic receptor blocker soquinolol". Arzneimittel-Forschung ...
... is a beta adrenergic receptor antagonist. J. Augstein, D. A. Cox and A. L. Ham., DE 2238504 (1973). Chem. Abstr. jte ...
... is a beta adrenergic receptor antagonist. Ban, T; Sada, S; Takahashi, Y; Sada, H; Fujita, T (1985). "Effects of para- ... substituted beta-adrenoceptor blocking agents and methyl-substituted phenoxypropanolamine derivatives on maximum upstroke ...
... is a beta adrenergic receptor antagonist. Hugues, FC; Julien, D; Bors, V; Mougeot, G; Marche, J (1980). "Determination ... in man of the beta blocking properties and the pharmacological half of pargolol (Author's transl)". Thérapie. 35 (4): 475-81. ...
Medications, including aspirin, β-adrenergic antagonists (beta blockers), ibuprofen, and penicillin. Food allergies such as ... In 1968 Andor Szentivanyi first described The Beta Adrenergic Theory of Asthma; in which blockage of the Beta-2 receptors of ... Szentivanyi's Beta Adrenergic Theory is a citation classic using the Science Citation Index and has been cited more times than ... Szentivanyi, Andor (1968). "The Beta Adrenergic Theory of the Atopic Abnormality in Asthma". J. Allergy. 42 (4): 203-232. doi: ...
... is a beta-adrenergic antagonist, or beta blocker. Typically moprolol is prescribed to treat hypertension, high blood ... A similar beta-blocker, metoprolol, that is very popular both overseas and in the US brought in an estimated €2.2 million in ... One significant clinical study in hypertension ran in 2013 using non-selective beta-blocker to study the effects on lowering ... Wong, Gavin WK; Wright, James M. Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension. doi: ...
... is a short-acting beta adrenergic receptor antagonist. Acylation of glycidol (2) with the acid chloride 1 produces ... 1. Novel .beta.-blockers with ultrashort duration of action". Journal of Medicinal Chemistry. 27 (8): 1007. doi:10.1021/ ...
... increase beta adrenergic receptors while decreasing alpha adrenergic receptors- which results in increased levels of ... GnRH antagonists (e.g., cetrorelix). *Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone ... D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, ... nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to ...
amyloid-beta binding. • signal transducer activity. • Wnt-protein binding. • protein binding. • protein kinase binding. • ... "Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action". Proc. Natl. Acad. Sci. U.S.A. 94 ... Holmen SL, Robertson SA, Zylstra CR, Williams BO (2005). "Wnt-independent activation of beta-catenin mediated by a Dkk1-Fz5 ... "Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin". Dev. Cell. 11 (2): 213-23 ...
Antagonists: AR-A000002. *Beta blockers (e.g., alprenolol, carteolol, isamoltane, oxprenolol, penbutolol, propranolol, ... α1-adrenergic receptor antagonist (Ki = 75 nM and 86 nM, respectively).[12] It possesses low or no affinity for the 5-HT1A, 5- ... HT2B, D2, and β-adrenergic, as well as at SERT and VMAT (Ki = all , 1 μM), but it does have some affinity for the α2-adrenergic ... Antagonists: ABT-354. *Atypical antipsychotics (e.g., aripiprazole, asenapine, clorotepine, clozapine, fluperlapine, ...
... is a selective β2 adrenergic receptor (adrenoreceptor) antagonist or beta blocker[1][2] . ICI binds to the β2 ... "Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic ... September 1989). "Molecular characterization of the human beta 3-adrenergic receptor". Science. 245 (4922): 1118-21. doi: ... Hillman KL, Doze VA, Porter JE (August 2005). "Functional characterization of the beta-adrenergic receptor subtypes expressed ...
Concomitant use of fenoldopam with a beta-blocker should be avoided if possible, as unexpected hypotension can result from beta ... and alpha-2 adrenoceptor antagonist activity.[5] D1 receptor stimulation activates adenylyl cyclase and raises intracellular ... fenoldopam is a selective D1 receptor agonist with no effect on beta adrenoceptors, although there is evidence that it may have ...
It behaves as an antagonist at α1-adrenergic, α2-adrenergic, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and dopamine D2, and as a partial ... Antagonists: AR-A000002. *Beta blockers (e.g., alprenolol, carteolol, isamoltane, oxprenolol, penbutolol, propranolol, ... Yohimbine is an alpha-2 adrenergic antagonist, and has been used in a variety of research projects. It is a veterinary drug ... February 2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, ...
... a specific antagonist radioligand for brain alpha 2-adrenergic receptors". European Journal of Pharmacology. 76 (4): 461-4. ... Antagonisti: Antipsihotici: Iloperidon • Risperidon • Sertindol; Beta blokatori: Alprenolol • Cianopindolol • Jodocianopindolol ... Rauvolscin deluje predominantno kao antagonist α2-adrenergičnog receptora.[2] On takođe deluje kao parcijalni agonist 5-HT1A ... Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL, Nelson DL (1998). „[3H]Rauwolscine: an antagonist radioligand for the ...
H1 Antagonist (Ki = 47 nM). *α1-adrenergic Antagonist (Ki = 10 nM) ... Antagonisti: Antipsihotici: Iloperidon • Risperidon • Sertindol; Beta blokatori: Alprenolol • Cianopindolol • Jodocianopindolol ... Smatra se da deluje kao antagonist na tim receptorima.[8][9] Ziprasidon takođe pokazuje umerenu inhibiciju sinaptičkog ponovnog ... a new antipsychotic with combined dopamine and serotonin receptor antagonist activity". J Pharmacol Exp Ther 275 (1): 101-13. ...
Antagonists: AR-A000002. *Beta blockers (e.g., alprenolol, carteolol, isamoltane, oxprenolol, penbutolol, propranolol, ... In addition to its actions as an antihistamine, captodiamine has been found to act as a 5-HT2C receptor antagonist and σ1 ... Antagonists: ABT-354. *Atypical antipsychotics (e.g., aripiprazole, asenapine, clorotepine, clozapine, fluperlapine, ... Beta blockers (e.g., alprenolol, carteolol, cyanopindolol, iodocyanopindolol, isamoltane, oxprenolol, penbutolol, pindobind, ...
Anti-glaucoma: adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors/hyperosmotics, cholinergics, miotics, ... dopamine antagonists, antihistamines, cholinergics, anticholinergics, emetics, cannabinoids, and 5-HT (serotonin) antagonists. ... Leukotriene antagonists For endocrine problemsEdit. androgens, antiandrogens, estrogens, gonadotropin, corticosteroids, human ... Affecting blood pressure/(antihypertensive drugs): ACE inhibitors, angiotensin receptor blockers, beta-blockers, α blockers, ...
... a 5-HT1A agonist/5-HT2A antagonist, and mesulergine, a 5-HT2A/2C antagonist.[15] The selectivity and affinity of ergolines for ... beta-Ergocryptine. CH(CH3)2. CH(CH3)CH2CH3 (S). Isoleucine ... Adrenergic receptor modulators. α1. *Agonists: 6-FNE. * ... The antagonist or agonist behavior of the ergolines are substrate dependent and mixed agonist/antagonist behaviors of ergoline ... beta-Ergosine. CH3. CH(CH3)CH2CH3 (S). Isoleucine ... These substances are neuroleptic and are either an antagonist ...
Re dhe vetëm beta receptor antagonist adrenergic, dichloroisoproterenol, gjithashtu ishte e pershkruara me larte dhe do të ... Alquist kishte raportuar më parë se efektet adrenergic mund të klasifikohen si alfa ose beta varësi të potencë relative të ... për shkak të efekteve beta adrenergic siç tregohet nga potencies relative e-isoproterenol l,-l epinephrine dhe-l norepinephrina ... për të treguar se efektet catecholamine në formimin AMP ciklike janë për shkak të efekteve përmes receptorit beta adrenergic. ...
Alpha-adrenergic agonist. *Beta blocker. *Dopamine agonist. *Dopamine antagonist. *Incretin mimetic. *Nonsteroidal anti- ... For receptors, these activities include agonist, antagonist, inverse agonist, or modulator. Enzyme target mechanisms include ...
Antagonists: AR-A000002. *Beta blockers (e.g., alprenolol, carteolol, isamoltane, oxprenolol, penbutolol, propranolol, ... Antagonists: ABT-354. *Atypical antipsychotics (e.g., aripiprazole, asenapine, clorotepine, clozapine, fluperlapine, ... Beta blockers (e.g., alprenolol, carteolol, cyanopindolol, iodocyanopindolol, isamoltane, oxprenolol, penbutolol, pindobind, ... Antagonists: Agomelatine. *Atypical antipsychotics (e.g., amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, ...
... with gamma decay following rapidly after beta decay: I. 53. 131. ⟶. β. +. ν. ¯. e. +. Xe. ∗. 54. 131. +. 606. keV. {\ ... Meta-[I-131]iodobenzylguanidine is a radio-labeled analog of the adrenergic blocking agent guanethidine.[37] Radioactivity is ... displaystyle {\ce {^{131}_{53}I-,\beta +{\bar {\nu }}_{e}+{^{131}_{54}Xe^{\ast }}+606keV}}}. Xe. ∗. 54. 131. ⟶. Xe. 54. 131. + ... Beta decay also produces an antineutrino, which carries off variable amounts of the beta decay energy. The electrons, due to ...
... an alpha-2 adrenergic agonist Irbesartan, an angiotensin II receptor antagonist Propranolol, a sympatholytic beta blocker ... Vasopressin receptor antagonists, such as conivaptan Acetazolamide, a carbonic anhydrase inhibitor Lithium was previously used ...
Assays have shown that selective NRIs have insignificant penchant for mACh, α1 and α2 adrenergic, or H1 receptors.[22] ... NMDA receptor antagonists (e.g., ketamine, dextromethorphan, methadone). *Opioids (e.g., hydrocodone, morphine, oxycodone, ... In addition, the TCAs interact with adrenergic receptors. This interaction seems to be critical for increased availability of ... Norepinephrine interacts with postsynaptic α and β adrenergic receptor subtypes and presynaptic α2 autoreceptors. The α2 ...
Beta blockers. *Calcium channel blockers. *renin-angiotensin system *ACE inhibitors. *Angiotensin II receptor antagonists ... "Combining opioid and adrenergic mechanisms for chronic pain". Postgraduate Medicine. 126 (4): 98-114. doi:10.3810/pgm.2014.07. ... Mu opioid; NMDA antagonist; SNRI.[99]. PO, IM, IV, SC.. Protein binding = 40%; extensive first-pass metabolism; half-life = 12- ... Mixed opioid agonist-antagonist.. IM, IV.. Volume of distribution = 9-12 L/kg; half-life = 2.2-2.7 hours.. Moderate-severe pain ...
SoRI-20040; Antagonist-like: SoRI-20041. *Adrenergic release blockers: Bethanidine. *Bretylium. *Guanadrel ...
Beta blockers. *Calcium channel blockers. *renin-angiotensin system *ACE inhibitors. *Angiotensin II receptor antagonists ... Adrenergic stimulants, such as ephedrine, may act by directly binding and activating the receptors that norepinephrine and ... but other drugs such as CB1 receptor antagonists exist in this class too.[25][26] Drugs used to treat sleep disorders such as ... on adrenergic receptors.[83] It is most usually marketed as the hydrochloride or sulfate salt. ...
Hydroxyzine - Antihistamine, 5-HT2A receptor antagonist.. *Propranolol - Sympatholytic, beta blocker.. *Clonidine - ... Sympatholytic, α2-adrenergic receptor agonist.. *Guanfacine - Sympatholytic, α2-adrenergic receptor agonist. ...
SoRI-20040; Antagonist-like: SoRI-20041. *Adrenergic release blockers: Bethanidine. *Bretylium. *Guanadrel ...
Serotonin antagonists and reuptake inhibitors *Etoperidone. *Nefazodone. *Trazodone. *Tricyclic antidepressants *Amitriptyline ...
Beta blockers. *Calcium channel blockers. *renin-angiotensin system *ACE inhibitors. *Angiotensin II receptor antagonists ... α-Adrenergic receptor agonists[edit]. Main article: α-Adrenergic receptor agonist. Common or widely marketed[edit]. * ... The vast majority of decongestants act via enhancing norepinephrine (noradrenaline) and epinephrine (adrenaline) or adrenergic ... Pseudoephedrine acts indirectly on the adrenergic receptor system, whereas phenylephrine and oxymetazoline are direct agonists ...
However, β2 adrenergic receptor agonists are not recommended to treat ARDS because it may reduce survival rates and precipitate ... Frequent infusions of beta-lactam antibiotics without exceeding total daily dose would help to keep the antibiotics level above ... and H2 antagonist are useful in a person with risk factors of developing upper gastrointestinal bleeding (UGIB) such as on ... minimum inhibitory concentration (MIC), thus providing better clinical response.[6] Giving beta-lactam antibiotics continuously ...
Antagonists: AR-A000002. *Beta blockers (e.g., alprenolol, carteolol, isamoltane, oxprenolol, penbutolol, propranolol, ... SoRI-20040; Antagonist-like: SoRI-20041. *Adrenergic release blockers: Bethanidine. *Bretylium. *Guanadrel ... Antagonists: ABT-354. *Atypical antipsychotics (e.g., aripiprazole, asenapine, clorotepine, clozapine, fluperlapine, ... Beta blockers (e.g., alprenolol, carteolol, cyanopindolol, iodocyanopindolol, isamoltane, oxprenolol, penbutolol, pindobind, ...
D2 receptor antagonists (e.g., domperidone, metoclopramide, risperidone) ... Follitropin beta. *Follitropin epsilon. *Menotropin (human menopausal gonadotropin). *Urofollitropin. *Varfollitropin alfa. * ...
Beta blockers (β-adrenergic antagonists) were once the most common medication given; however, they have been shown to be ...
... on beta blockers and cimetidine, and the discovery of statins by Akira Endo.[15] Another champion of the approach of developing ... see antagonist and agonist): if the target is a protein kinase, the chemicals will be tested for their ability to inhibit that ... who pioneered the first inhaled selective beta2-adrenergic agonist for asthma, the first inhaled steroid for asthma, ranitidine ...
... is a non-cardioselective beta blocker, that is, it blocks beta-1 receptors as well as beta-2 receptors. The latter ... Levobunolol (trade names AKBeta, Betagan, Vistagan, among others) is a non-selective beta blocker. It is used topically in the ... Further information: Beta blocker § Adverse effects. The most common side effect is eye irritation felt as stinging or burning ... Like other beta blockers, and unlike the anti-glaucoma medication pilocarpine, levobunolol has no effect on accommodation and ...
Beta Blockers Definition Beta blockers are medicines that affect the bodys response to certain nerve impulses. This, in turn, ... Beta blockers. Definition. Beta blockers, also known as beta antagonists, are a class of drugs that were first developed for ... Home Literature and the Arts Art and Architecture Art: General Adrenergic beta-antagonists ... Beta blockers, also known as beta antagonists, are a class of drugs that were first developed for the treatment of certain ...
Comparison of Adrenergic Beta-receptor Antagonists in Angina Pectoris Br Med J 1973; 1 :138 ... Comparison of Adrenergic Beta-receptor Antagonists in Angina Pectoris. Br Med J 1973; 1 doi: ... suggests that metabolic breakdown products are probably of therapeutic importance only in so far as they antagonize beta- ...
A Beta-2 adrenergic antagonist (β2-adrenoceptor antagonist) is an adrenergic antagonist which blocks the beta-2 adrenergic ... ICI-118,551 Butaxamine Propranolol Betablocker Beta-2 adrenergic receptor Beta2-adrenergic agonist Bilski, AJ; Halliday, SE; ... Fitzgerald, JD; Wale, JL (1983). "The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551)". J Cardiovasc ... an antagonist for β2 and for β1 or β3 adrenoceptors) like the non-selective betablocker Propranolol. ...
A Beta-3 adrenergic antagonist (β3-adrenoceptor antagonist) is an adrenergic antagonist which blocks the Beta-3 adrenergic ... "Potent and selective human beta(3)-adrenergic receptor antagonists". The Journal of Pharmacology and Experimental Therapeutics ... SR 59230A Carvedilol Betablocker Beta-3 adrenergic receptor Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, ... an antagonist for β3 and for β1 or β2 adrenoceptors) like the non-selective betablocker Carvedilol. ...
Adrenergic beta Antagonists. Drugs that bind to but do not activate beta-Adrenergic Receptors thereby blocking the actions of ... beta-Adrenergic Agonists. Adrenergic beta-antagonists are used for treatment of Hypertension, Cardiac Arrhythmias, Angina ...
... beta-Adrenergic , Antagonists, beta-Adrenoceptor , beta Adrenergic Antagonists , beta-Adrenergic Antagonists , beta Adrenergic ... Adrenergic beta-Antagonists Equivalent Terms Adrenergic beta Antagonists , Adrenergic beta-Blockers , Adrenergic beta Receptor ... beta-Adrenoceptor Antagonists , beta-Antagonists, Adrenergic , beta Blockers, Adrenergic , beta-Blockers, Adrenergic , beta- ... Adrenergic Agents ← Adrenergic AntagonistsAdrenergic beta-Antagonists 2.. Chemicals ← Chemical Actions and Uses ← ...
... beta,2-adrenergic,receptor,antagonists,using,CypHer5E,and,IN,Cell,Analyzer,1000,biological,advanced biology technology,biology ... has been used to obtain dose-response and rank-order potency data for both agonist and antagonist treatment of β2-adrenergic ... Introduction CypHer ™ 5 a pH sensitive dye has shown utility in β2-adrenergic receptor agonist screening (1). CypHer5 ... Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000 ...
Inverse agonist activity of beta-adrenergic antagonists.. P Chidiac, T E Hebert, M Valiquette, M Dennis and M Bouvier ... Inverse agonist activity of beta-adrenergic antagonists.. P Chidiac, T E Hebert, M Valiquette, M Dennis and M Bouvier ... Inverse agonist activity of beta-adrenergic antagonists.. P Chidiac, T E Hebert, M Valiquette, M Dennis and M Bouvier ... Inverse agonist activity of beta-adrenergic antagonists. Message Subject (Your Name) has forwarded a page to you from Molecular ...
Histamine H2 Antagonists. *Alpha/Beta Adrenergic Agonists. *Local Anesthetics, Amides. *Show All ... Alpha/Beta Adrenergic Agonists. Class Summary. These agents may be used to treat nasal congestion. ... Histamine H2 Antagonists. Class Summary. H2 blockers are reversible competitive blockers of histamine at H2 receptors, ... Histamine 2 (H2)-receptor antagonists should be administered preoperatively to prevent increase in gastric secretion during the ...
Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in ... AdolescentAdrenergic beta-AgonistsAdrenergic beta-AntagonistsAdultAlbuterolAnorexia NervosaArea Under CurveAtenololFemaleGrowth ... We studied the effect of atenolol (ATE), a beta 1-adrenergic antagonist, and salbutamol (SALB), a beta 2-adrenergic agonist, on ... METHODS: We studied the effect of atenolol (ATE), a beta 1-adrenergic antagonist, and salbutamol (SALB), a beta 2-adrenergic ...
Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions at 5 x 10-5 M by force ...
Binding of adrenergic beta-receptor antagonists to human serum albumin. by C Appelgren et al. ... Binding of adrenergic beta-receptor antagonists to human serum albumin.. @article{Appelgren1974BindingOA, title={Binding of ... adrenergic beta-receptor antagonists to human serum albumin.}, author={C Appelgren and Karl O. Borg and Rolf Elofsson and Karl ... The relationship between beta-adrenoceptors and adrenergic responsiveness in trout (Oncorhynchus mykiss) and eel (Anguilla ...
... and beta 2 adrenergic antagonists on the Na and K concentrations of sympathetic-nerve stimulated rat saliva.: Selective alpha ... Effects of alpha, beta 1, and beta 2 adrenergic antagonists on the Na and K concentrations of sympathetic-nerve stimulated rat ... Selective alpha and beta 1 and beta 2 adrenergic antagonists were used with electrical stimulation of the sympathetic ... innervation to parotid and submandibular glands of rats in order to delineate the role of the beta 1 and beta 2 adrenoceptors ...
What is Adrenergic beta-antagonists? Meaning of Adrenergic beta-antagonists medical term. What does Adrenergic beta-antagonists ... Looking for online definition of Adrenergic beta-antagonists in the Medical Dictionary? Adrenergic beta-antagonists explanation ... beta blocker. (redirected from Adrenergic beta-antagonists). Also found in: Dictionary, Thesaurus, Encyclopedia. beta blocker. ... Adrenergic beta-antagonists , definition of Adrenergic beta-antagonists by Medical dictionary https://medical-dictionary. ...
Learn and reinforce your understanding of Adrenergic antagonists: Beta blockers. ... Beta blockers Videos, Flashcards, High Yield Notes, & Practice Questions. ... Lets focus on beta receptors, which have two main subtypes: beta1 (β1) and beta2 (β2). Beta1 adrenergic receptors are mainly ... Actually, pindolol is not a pure antagonist, but a partial agonist. This means that, when bound to a beta receptor, it very ...
This group of antagonists are generally used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, ... Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta- ... Adrenergic beta-Antagonists. Known as: beta-adrenergic blockers, Beta-Adrenergic Blocking Agent, Adrenergic beta-Receptor ... Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta- ...
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention ...
Adrenergic beta-1 Receptor Antagonists. Heres what weve found for you. Adrenergic beta-1 Receptor Antagonists Adrenergic beta ... BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-1-adrenergic antagonist ... SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-adrenergic ... approved Adrenergic beta-1 Receptor Antagonists BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING ...
Save money on Adrenergic beta-1 Receptor Antagonists with free prescription coupons from RX24Drugs. We support biggest US ...
Labetalol is an alpha-1 and beta adrenergic blocker used to treat high blood pressure. It works by blocking these adrenergic ...
Find out information about beta-adrenergic antagonist. 1. any muscle that opposes the action of another 2. a drug that ... counteracts the effects of another drug A molecule that bears sufficient structural... Explanation of beta-adrenergic ... antagonist. (redirected from beta-adrenergic antagonist). Also found in: Dictionary, Thesaurus, Medical, Legal. antagonist. 1. ... Beta-adrenergic antagonist , Article about beta-adrenergic antagonist by The Free Dictionary https://encyclopedia2. ...
HomeThe role of beta-adrenergic receptor antagonists in the p. The role of beta-adrenergic receptor antagonists in the p. By ...
Mechanism of broncho-constrictor action of some adrenergic beta-receptor antagonists. Mechanism of broncho-constrictor action ... Acetanilides/pharmacology , Adrenergic beta-Antagonists/pharmacology , Amino Alcohols/pharmacology , Animals , Bronchi/drug ... Adrenergic beta-Antagonists / Amino Alcohols / Animals / Acetanilides / Nitrobenzenes Language: English Year: 1972 Type: ... Adrenergic beta-Antagonists / Amino Alcohols / Animals / Acetanilides / Nitrobenzenes Language: English Year: 1972 Type: ...
Adrenergic Agents. Adrenergic beta-Antagonists. Adrenergic Antagonists. Neurotransmitter Agents. Molecular Mechanisms of ... Experimental: Adrenergic Blockade Propranolol and Clonidine. Drug: IV Propranolol and Per Tube Clonidine 1 mg IV q6h ... DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury. This study has been ... Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH ...
... a nonselective beta-adrenergic receptors agonist) and inhibited by metoprolol (a selective beta1 antagonist), strongly ... Nuclear targeting of FBPase in HL-1 cells is controlled by beta-1 adrenergic receptor-activated Gs protein signaling cascade ... suggesting that nucleo-cytoplasmic shuttling of FBPase is under the control of beta1-adrenergic receptor-dependent Gs protein ...
beta-adrenergic antagonist An agent that binds to but does not activate beta. -adrenergic receptors thereby blocking the ... beta-adrenergic antagonist An agent that binds to but does not activate beta. -adrenergic receptors thereby blocking the ... beta. -adrenergic agonists. beta. -Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina ... beta. -adrenergic agonists. beta. -Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina ...
Adrenergic beta-Antagonists/therapeutic use. *Endoscopy, Gastrointestinal/methods*. *Esophageal and Gastric Varices/prevention ...
Adrenergic beta-Antagonists. LinkOut - more resources. Full Text Sources. *Atypon - PDF. *Atypon ... and there was no interaction between the use or nonuse of beta-blockade and the predictive power of exercise capacity. Each 1- ...
  • A Beta-2 adrenergic antagonist (β2-adrenoceptor antagonist) is an adrenergic antagonist which blocks the beta-2 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β2 adrenoceptors) like Butaxamine and ICI-118,551, or non-specifically (an antagonist for β2 and for β1 or β3 adrenoceptors) like the non-selective betablocker Propranolol. (
  • A Beta-3 adrenergic antagonist (β3-adrenoceptor antagonist) is an adrenergic antagonist which blocks the Beta-3 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β3 adrenoceptors) like L-748,328, L-748,337 and SR 59,230A or non-specifically (an antagonist for β3 and for β1 or β2 adrenoceptors) like the non-selective betablocker Carvedilol. (
  • Drugs that bind to but do not activate beta-Adrenergic Receptors thereby blocking the actions of beta-Adrenergic Agonists . (
  • CypHer5E, consequently, can be used to screen for novel antagonists of known receptors and for potential ligands of non-G-protein coupled receptors (5) and orphan receptors. (
  • The H2 antagonists are highly selective, they do not affect the H1 receptors, and they are not anticholinergic agents. (
  • Alpha blockers and beta blockers are two types of postsynaptic anti-adrenergic medications that prevent their respective receptors from being stimulated by catecholamines, like norepinephrine and epinephrine . (
  • These two catecholamines activate the adrenergic receptors on many different organs, which allows the sympathetic nervous system to trigger the fight or flight response that increases the heart rate and blood pressure , as well as slowing down digestion. (
  • Now, there are two main groups of adrenergic receptors: the alpha receptors, and beta receptors . (
  • Let's focus on beta receptors, which have two main subtypes: beta1 (β1) and beta2 (β2). (
  • Beta1 adrenergic receptors are mainly located in the heart, where they increase the heart rate and contractility , which helps pump out more blood. (
  • Moving on to beta2 adrenergic receptors, these are found on smooth muscle cells in the walls of blood vessels supplying skeletal muscles and the brain, which leads to vasodilation and increased blood flow to these tissues. (
  • In the lungs, beta2 adrenergic receptors cause bronchodilation , and that increases oxygen delivery to cells. (
  • Alright, so medications that act on peripheral post-synaptic adrenergic neurons to block adrenergic receptors are called peripheral post-synaptic anti-adrenergics. (
  • And based on the type of receptors they block, they are divided into two main categories - alpha blockers and beta blockers. (
  • Adrenergic beta-1 Receptor Antagonists Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (
  • Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. (
  • It works by blocking these adrenergic receptors, which slows sinus heart rate, decreases peripheral vascular resistance, and decreases cardiac output. (
  • Beta-adrenergic antagonists , or beta-blockers, also might reduce stress-hormone-induced memory consolidation and fear conditioning by blocking postsynaptic norepinephrine receptors and impairing emotional memory, he said. (
  • α adrenergic receptors , preventing adrenaline and noradrenaline from binding. (
  • An agent that binds to but does not activate beta -adrenergic receptors thereby blocking the actions of endogenous or exogenous beta -adrenergic agonists. (
  • Mechanism of action - non-selectively antagonizes beta-1 and beta-2 adrenergic receptors c. (
  • Inhibit or reverse the actions of the parasympathetic nervous system and bind with cholinergic receptors and prevent binding of acetylcholine (they are antagonists). (
  • Beta blockers block the action of endogenous catecholamines ( epinephrine (adrenaline) and norepinephrine (noradrenaline) in particular), on β- adrenergic receptors , part of the sympathetic nervous system which mediates the " fight or flight " response. (
  • β 1 -Adrenergic receptors are located mainly in the heart and in the kidneys. (
  • Some beta blockers (e.g. labetalol and carvedilol ) exhibit mixed antagonism of both β- and α 1 -adrenergic receptors, which provides additional arteriolar vasodilating action. (
  • By this second component of the mechanism, the same stimulus directly acts on the carbonic anhydrase I isozyme (that might be functionally coupled with adrenergic receptors), so that its activation ensures an adequate pH for stimulus-receptor coupling for signal transduction into the cell, resulting in vasoconstriction. (
  • Important factors in the response of any cell or organ to sympathomimetic amines are the density and proportion of alpha- and beta-adrenergic receptors (3,4). (
  • Studies on DNA cloning have demonstrated the existence of at least nine types of adrenergic receptors (5). (
  • The norepinephrine provided by the LC acts at the medial septal area (MSA) and the medial preoptic area (MPOA) to activate waking-active neurons ( via alpha-1 adrenergic receptors) and inhibit sleep-active neurons ( via alpha-2 adrenergic receptors). (
  • There are also beta-1, beta-2, and beta-3 adrenergic receptors in the MSA and MPOA ( 4 ). (
  • The intracellular cAMP content of Sf9 cells cultured in serum-free medium was also increased by the expression of beta 2AR, and that increase was reversed by timolol and propranolol, consistent with observations in membrane preparations. (
  • Individual sensitivity to beta-blockade may be significantly reduced in those patients who have tolerated therapeutic doses of up to 4 g of propranolol daily and in patients who have sustained deliberate overdoses of both practolol and propranolol without serious adverse effects. (
  • This reduction in QTc derived entirely from a decrease in the QTc among patients with a baseline abnormal QTc, in whom the shortening in the QTc was greater with propranolol than with either nadolol or metoprolol (p=0.04) since the change in QTc was comparable in all three beta blocker groups with a normal or borderline baseline QTc (p=0.8). (
  • Propranolol was the first clinically useful beta adrenergic receptor antagonist . (
  • Propranolol, a non-selective beta-adrenergic antagonist with good penetration of the blood-brain barrier, has not been investigated for this purpose. (
  • Propranolol is a non-selective beta-adrenergic antagonist that has good penetration of the blood-brain barrier ( 21 ). (
  • In AN, in contrast to normal subjects, cholinergic antagonists and agonists, whose action is somatostatin (SS)-mediated, have reduced and absent effects on the GH response to growth hormone-releasing hormone (GHRH). (
  • To further clarify the neural control of AH secretion in AN, we evaluated the effects of beta-adrenergic agonists and antagonists, which are known to inhibit and increase, respectively, the GHRH-induced GH secretion in normal subjects. (
  • It is used as an adjunct to inhaled beta -2 selective agonists and systemically administered corticosteroids. (
  • The investigators were interested in albuterol because other beta-2 agonists as a class had improved strength and function of healthy and diseased muscle in animal studies and human trials. (
  • Beta adrenergic agonists 3. (
  • How does inuslin, beta adrenergic agonists cause hypokalemia? (
  • Thus, prospective studies in animals and patients at different stages of heart failure should lead to identify the best therapeutic window to use ß 3 -AR agonists and/or antagonists. (
  • We studied the relationship between alpha- and beta-adrenergic agonists and the activity of carbonic anhydrase I and II in erythrocyte, clinical and vessel studies. (
  • We believe that adrenergic agonists may have a dual mechanism of action: the first one consists of a catecholamine action on its receptor with the formation of a stimulus-receptor complex. (
  • Our previous work has shown that alpha- and beta-adrenergic agonists activated purified and red cell CA while adrenergic antagonists inhibited CA and reduced the activating effect of agonists on this enzyme (15,16). (
  • In the present investigation we studied the relationship between alpha- and beta-adrenergic agonists and CA activity in vasoconstriction mechanism. (
  • Despite this early evidence supporting chronic use of beta blockers in asthma, there is concern in 2 major regards:their potential to cause acute airway narrowing (irrespective of longterm benefit) and the possibility that they could block the reliever action of beta agonists. (
  • Recent studies have examined the effectiveness of alpha-2 adrenergic agonists for controlling delirium and agitation. (
  • Introduction CypHer ™ 5 a pH sensitive dye has shown utility in β2-adrenergic receptor agonist screening (1). (
  • CypHer5 has been used to obtain dose-response and rank-order potency data for both agonist and antagonist treatment of β2-adrenergic receptor expressing cells (2). (
  • Agonist and antagonist controls were placed symmetrically in columns 1 and 12 of each plate. (
  • Twelve replicate wells contained a known agonist, isoproterenol, and four replicate wells contai ned a known antagonist, alprenolol, each diluted in 0.01% DMSO. (
  • Inverse agonist activity of beta-adrenergic antagonists. (
  • Agonist-independent properties of the human beta 2-adrenergic receptor (beta 2AR) were studied using the baculovirus expression system in Sf9 cells. (
  • In the absence of agonist but in the presence of GTP, membranes from cells expressing the beta 2AR exhibited higher levels of cAMP production than did membranes from uninfected cells or from cells infected with wild-type baculovirus. (
  • We studied the effect of atenolol (ATE), a beta 1-adrenergic antagonist, and salbutamol (SALB), a beta 2-adrenergic agonist, on the GHRH-induced GH release in 10 patients with AN and in 10 normal age-matched women (NW). (
  • Synonyms : 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol, 1-(Isopropylamino)-3-[P-(cyclopropylmethoxyethyl)phenoxy]-2-propanol, Betaxololum Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-1-adrenergic antagonist with no partial agonist activity. (
  • This can be calculated for a given antagonist by determining the concentration of antagonist needed to elicit half inhibition of the maximum biological response of an agonist . (
  • Asymptomatic intoxication occurs mainly in healthy persons with tolerance to these drugs who ingest beta-blockers that lack membrane-stabilizing effects or have a partial agonist effect (eg, pindolol). (
  • In a small placebo-controlled trial, the beta-2 agonist albuterol improved lean body mass in boys with DMD, but there were no significant improvements in manual muscle tests and other measures of physical functioning. (
  • Lead investigator Melissa J. Spencer, PhD, associate professor of neurology at the David Geffen School of Medicine at the University of California-Los Angeles, said the findings suggest that albuterol, a beta-2 adrenegic agonist and an FDA-approved drug for asthma, might also help retain muscle tissue in boys with DMD. (
  • Importance of Alpha - adrenergic Receptor Subtypes in Regulating of Airways Tonus at Patients with Bronchial Asthma In this work, effect of Tamsulosin hydrochloride as antagonist of alpha1A and alpha1B- adrenergic receptor and effect of Salbutamol as agonist of beta2- adrenergic receptor in patients with bronchial asthma and increased bronchial reactibility was studied.Parameters of the lung function are determined by Body plethysmography. (
  • Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. (
  • These agents are capable of exerting low level agonist activity at the β-adrenergic receptor while simultaneously acting as a receptor site antagonist . (
  • Dexmedetomidine is a potent alpha-2 adrenergic agonist that binds to the alpha-2 adrenergic receptor subtype A at the LC, resulting in almost complete inhibition of the LC, which has a sedative effect ( 5 , 6 ). (
  • Beta blockers are medicines that affect the body's response to certain nerve impulses. (
  • The main use of beta blockers is to treat high blood pressure . (
  • Beta blockers, also known as beta-adrenergic blockers, are available only with a physician's prescription. (
  • Timolol and certain other beta blockers are also sold in eye drop form for treating glaucoma. (
  • Eye drops that contain beta blockers include betaxolol (Betoptic), cartelol (Ocupress), and timolol (Timoptic). (
  • Some conditions may get worse when patients stop taking beta blockers abruptly. (
  • Seeing a physician regularly while taking beta blockers is important. (
  • Beta blockers will not cure high blood pressure, but will help control the condition. (
  • Anyone taking beta blockers for high blood pressure should not take any other prescription or over-the-counter medicine without first checking with his or her physician. (
  • Anyone who is taking beta blockers should be sure to tell the health care professional in charge before having any surgical or dental procedures or receiving emergency treatment. (
  • Some beta blockers may change the results of certain medical tests. (
  • Some people feel drowsy, dizzy, or lightheaded when taking beta blockers. (
  • Beta blockers may increase sensitivity to cold, especially in older people or people who have poor circulation. (
  • Now, beta blockers are subdivided into three generations. (
  • Beta-adrenergic antagonists , more commonly known as beta blockers, are identified easily by the name ending olol. (
  • Despite the importance of beta-blockers for secondary prevention after acute myocardial infarction (AMI), several studies have suggested that they are substantially underutilized, particularly in older patients. (
  • To describe the contemporary national pattern of beta-blocker prescription at hospital discharge among patients aged 65 years or older with an AMI, to identify the most important predictors of the prescribed use of beta-blockers at discharge, and to determine the independent association between beta-blockers at discharge and mortality in clinical practice. (
  • Among the 45308 patients without contraindications to beta-blockers, 22665 (50.0%) had a beta-blocker as a discharge medication. (
  • After adjusting for potential confounders, beta-blockers were associated with a 14% lower risk of mortality at 1 year after discharge. (
  • Geographic factors and physician specialty are independently associated with the decision to use beta-blockers. (
  • Elderly patients who are prescribed beta-blockers at discharge have a better survival rate, consistent with the findings of randomized controlled trials of younger and lower-risk populations. (
  • Beta-blockers are established drugs in heart failure with reduced ejection fraction, but their role in heart failure with preserved ejection fraction (HFpEF) is not established. (
  • Hence, we undertook a meta-analysis to evaluate the efficacy of beta-blockers on mortality and morbidity in HFpEF patients. (
  • A systematic search using PubMed, Embase, Scopus and Cochrane databases was performed to identify all relevant studies on beta-blockers and HFpEF. (
  • A random-effects model was performed to assess the role of beta-blockers on all-cause mortality and HF hospitalization. (
  • Observational studies showed a significant benefit from the use of beta-blockers for all-cause mortality, but not for HF hospitalization. (
  • Further large sampled well-conducted randomized trials are warranted to confirm the effects of beta-blockers on mortality and hospitalization. (
  • They report such a case in a young woman with end-stage renal disease requiring peritoneal dialysis who was receiving antihypertensive treatment with atenolol, which unlike most beta-blockers is excreted primarily by the kidney, and which is poorly cleared by peritoneal dialysis. (
  • Beta-blockers that are not sustained-release formulations are all rapidly absorbed from the gastrointestinal tract. (
  • Antihypertensive agents include diuretics, alpha-adrenergic and beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents. (
  • Numerous studies have shown a beneficial effect of combination therapy with beta-blockers and calcium antagonists in patients with anginal syndrome and/or hypertension. (
  • Various combinations of calcium antagonists and beta-blockers were associated with the CVADRs. (
  • Enhanced therapeutic monitoring may be warranted when calcium antagonists are combined with beta-blockers. (
  • However, the effect of beta- blockers and a physical training program to modulate this sympathetic activation during this valve disease is unknown. (
  • Mullins ME, Horowitz BZ, Linden DHJ, Smith GW, Norton RL, Stump J. Life-Threatening Mibefradil Interaction with Beta-Blockers and Dihydropyridine Calcium Channel Blockers. (
  • What are Adrenergic Antagonists (blockers)/ Sympatholytic Agents used for? (
  • How do Adrenergic Antagonists (blockers)/ Sympatholytic Agents work? (
  • What are the side effects of Adrenergic Antagonists (blockers)/ Sympatholytic Agents? (
  • Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2: Higher Recurrence of Events Under Metoprolol. (
  • Although a number of approaches (e.g., beta blockers, permanent pacing, left cervicothoracic sympathectomy, ICD implantation) have been proposed as therapeutic options for patients with the congenital long QT syndromes (LQTS), beta blocker therapy has served as the mainstay of treatment for the majority of these patients. (
  • 1-4 Furthermore, the published guidelines recommended an ICD only for LQTS patients who experience syncope or VT while taking a beta blocker (class IIa indication, level of evidence B). 5 However, there is a paucity of data on both the differential electrophysiological and clinical effects of the available beta blockers. (
  • Although clinicians often view beta blockers as similar in their pharmacological characteristics, electrocardiographic manifestations, electrophysiologic properties, and clinical efficacy, it has been established that there are a number of important differences among beta blockers. (
  • Beta blockers (sometimes written as β-blockers ) are a class of drugs used for various indications, but particularly for the management of cardiac arrhythmias and cardioprotection after myocardial infarction . (
  • Whilst once first-line treatment for hypertension , their role was downgraded in June 2006 in the United Kingdom to fourth-line as they do not perform as well as other drugs, particularly in the elderly, and there is increasing evidence that the most frequently used beta-blockers especially in combination with thiazide -type diuretics carry an unacceptable risk of provoking type 2 diabetes . (
  • Beta blockers inhibit these normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. (
  • It is therefore expected that non-selective beta blockers have an antihypertensive effect. (
  • The antiarrhythmic effects of beta blockers arise from sympathetic nervous system blockade - resulting in depression of sinus node function and atrioventricular node conduction, and prolonged atrial refractory periods . (
  • Some beta blockers (e.g. oxprenolol and pindolol ) exhibit intrinsic sympathomimetic activity (ISA). (
  • They may also be less effective than other beta blockers in the management of angina and tachyarrhythmia . (
  • Intraoperative hemodynamic values were similar for the shunt and control groups as well as for patients receiving and not receiving preoperative beta blockers. (
  • The current study found an association between regular preoperative use of beta blockers and intraoperative cerebral ischemia in patients undergoing carotid endarterectomy . (
  • The systolic blood pressure increase was 3 mmHg in a subgroup of patients concomitantly prescribed angiotensin converting enzyme inhibitors or calcium channel blockers and 6 mmHg among those prescribed a beta-adrenergic blocker. (
  • Beta-blockers are medicines that work by temporarily stopping or reducing the body's natural 'fight-or-flight' responses. (
  • Beta-blockers are prescribed in conditions where the heart rate needs to be slowed. (
  • Doctors commonly recommend beta-blockers for patients with irregular heartbeats, angina, and high blood pressure. (
  • Beta-blockers also offer relief for glaucoma, overactive thyroid, and anxiety. (
  • Taking beta-blockers can cause dizziness, cold hands and feet, weight gain, and fatigue . (
  • Beta-blockers slow the heart beat to treat conditions in which the heart is under stress. (
  • Beta-blockers block the hormones adrenaline and noradrenaline in the sympathetic nervous system. (
  • Beta-blockers also obstruct the production of angiotensin II, a hormone produced by the kidneys. (
  • Beta-blockers can help to relieve the 'fight-or-flight' reactions that fuel anxiety. (
  • Beta-blockers block the effects of stress hormones. (
  • Beta-blocking agents have been less well studied for ICU delirium, although beta-blockers are known to have beneficial effects on anxiety, posttraumatic Stress Disorder (PTSD) and aggressive behavior in a variety of populations ( 16 - 20 ). (
  • These data reveal an exaggerated somatotrope responsiveness to GHRH in AN that is not further increased by beta-adrenergic blockade, while is abolished by beta-adrenergic activation. (
  • Absolute peak exercise capacity was a stronger predictor of the risk of death than the percentage of the age-predicted value achieved, and there was no interaction between the use or nonuse of beta-blockade and the predictive power of exercise capacity. (
  • The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI). (
  • The primary hypothesis is that adrenergic blockade after severe TBI will be associated with increased ventilator-free days. (
  • Beta adrenergic blockade in hypertension. (
  • Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha - adrenergic Blockade Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha - adrenergic Blockade - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. (
  • Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure. (
  • however, whether the mechanisms for the effects of beta-blockade in CHF are due to modulating chronotropy, inotropy, or both remains unknown. (
  • To address this issue, left ventricular function and isolated myocyte function were examined with chronic beta-blockade in a rapid pacing model of CHF, thereby eliminating potential chronotropic effects of beta-blockade. (
  • This dosage schedule for beta-blockade was chosen because catecholamines are persistently elevated by day 14 in this model of CHF. (
  • 05). Thus, institution of beta-1-selective blockade during the development of SVT-induced CHF altered the temporal characteristics of the myocyte contraction process, which resulted in improved myocyte shortening. (
  • CONCLUSIONS: In a model of CHF due to the maintenance of a chronically elevated heart rate, institution of beta-1-selective blockade during the progression of the CHF process minimally affected left ventricular size and function. (
  • At the level of the myocyte, chronic beta-1-receptor blockade prolonged the contraction interval and thereby increased myocyte shortening. (
  • These unique results suggest that a contributory mechanism for the effects of beta-blockade in the setting of CHF is chronotropic modulation. (
  • The second rise in PRA was increased by 30% with alpha-adrenergic blockade. (
  • The recommended dosage depends on the type, strength, and form of beta blocker and the condition for which it is prescribed. (
  • Synonyms : 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol, 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide, 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide, Atenololum Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. (
  • Labetalol is an alpha-1 and beta adrenergic blocker used to treat high blood pressure. (
  • The enantiomers of the hydrophilic beta-adrenergic blocker CGP-12177 have been synthesized and the S-enantiomer radiolabeled with tritium. (
  • Of the 36795 patients who were not receiving beta-blocker therapy on admission, 16006 (43.5%) had therapy initiated on or before discharge. (
  • Demographic and clinical variables explained relatively little of the variation in the initiation of beta-blocker therapy. (
  • The New England region had significantly higher use of beta-blocker therapy than the rest of the country. (
  • Many ideal patients for beta-blocker therapy are not prescribed these drugs at discharge following AMI. (
  • However, in the two RCTs, the use of beta-blocker was not associated with all-cause mortality [RR 0.94 (0.67-1.32), p = 0.72] or HF hospitalization [0.90 (0.54-1.49), p = 0.68]. (
  • Ideally, the clinician should determine the specific beta-blocker involved, the quantity, and the time of the overdose. (
  • When a history of intentional overdose is lacking, beta-blocker toxicity can go unrecognized as a cause of bradycardia and hypotension. (
  • Hoot et al note the risk of chronic beta-blocker toxicity in patients with impaired clearance. (
  • If a patient is bradycardic and hypotensive, the clinician should consider a beta-blocker or calcium channel blocker overdose . (
  • Myocardial conduction delays with decreased contractility typify the acute beta-blocker ingestion. (
  • In all clinically significant beta-blocker overdoses, symptoms develop within 6 hours. (
  • Conversely, circulatory collapse may occur in patients with preexisting cardiac failure when sympathetic drive is inhibited by even a small dose of a particular beta-blocker. (
  • 60 bpm) defines severe beta-blocker toxicity. (
  • Among categorical data, in addition to the epidemiological variables such as age and sex, we considered factors related to arterial and portal hypertension: we therefore evaluated the recipient gender, the presence in the medical history of previous surgery or a TACE (transarterial chemo-embolization), arterial hypertension, antihypertensive therapy, beta-blocker therapy, oesophageal varices, the type of liver disease, and the type of viral liver disease (hepatitis B and C). (
  • Beta Blocker (e.g. (
  • Use of calcium antagonist plus beta-blocker may unpredictably cause serious hemodynamic events, marked suppression of sinus node activity, and prolongation of atrioventricular conduction in some patients. (
  • Beta-Blocker Therapy After Myocardial Infarction: More Questions Than Answers. (
  • Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. (
  • In follow-up, the risk reduction for a BCE was correlated with greater QTc shortening on beta blocker therapy. (
  • These agents, therefore, may be useful in individuals exhibiting excessive bradycardia with sustained beta blocker therapy. (
  • A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). (
  • Preoperative beta blocker use associated with cerebral ischemia during carotid endarterectomy. (
  • P = 0.005) for the association between use of a beta blocker and shunting. (
  • There are many different brands of beta-blocker. (
  • The high pressure within the eyeball is reduced using beta-blocker eye drops. (
  • The objective of this study is to establish how best to reverse the short term effects of a single dose of beta blocker. (
  • Adrenergic beta-antagonists are used for treatment of Hypertension , Cardiac Arrhythmias , Angina Pectoris , Glaucoma , Migraine Headaches , and Anxiety . (
  • Synonyms : (RS)-Metoprolol, 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol, Metoprolol Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists Metoprolol is a cardioselective β1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. (
  • CVADRs are not uncommon in elderly patients with ischemic heart disease and/or hypertension treated with the concomitant use of calcium antagonist and beta-adrenergic blocking drugs. (
  • Selective alpha and beta 1 and beta 2 adrenergic antagonists were used with electrical stimulation of the sympathetic innervation to parotid and submandibular glands of rats in order to delineate the role of the beta 1 and beta 2 adrenoceptors in regulation of salivary flow rate, Na reabsorption and K secretion from these glands. (
  • Animal and human evidence indicates a potential therapeutic benefit for β-adrenergic receptor antagonists, selective cyclooxygenase inhibitors, and anti-fibrinolytics administered through the perioperative period. (
  • The beta-adrenoblockers anapriline and visken and the calcium antagonist corinfar were studied for effects on the atherogenic properties of the sera from patients with coronary heart disease who took the drugs. (
  • beta-blocking drugs may cause hypoglycemia by inhibiting glycogenolysis. (
  • Synonyms : (+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol, (RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol, Bisoprolol, Bisoprololum Status : approved Antihypertensive Agents BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Adrenergic beta-1 Receptor Antagonists Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. (
  • Synonyms : (+-)-Practolol, 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol, 4′-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide, N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide, Practololum, Tocris-0831 Status : approved Adrenergic beta-1 Receptor Antagonists BETA BLOCKING AGENTS CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Anti-Arrhythmia Agents A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. (
  • Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. (
  • Equally, the similarity in the symptomatic, circulatory, and electrocardiographic response to the intravenous and oral preparations suggests that metabolic breakdown products are probably of therapeutic importance only in so far as they antagonize beta-receptor activity. (
  • The data demonstrate that the β2-adrenergic receptor CypHer5E antagonist assay used in conjunction with IN Cell Analyzer 1000 was able to identify all specific β2-adrenergic receptor antagonists and additional structurally related compounds present in the LOPAC compound library. (
  • A family of compounds structurally related to the beta adrenergic blocking agent sotalol (MJ 1999) was investigated for potency with respect to inhibition of the aforementioned metabolic responses. (
  • ß(3) adrenergic stimulation of the cardiac Na+−K + pump by reversal of an inhibitory oxidative modification. (
  • Acute and chronic intrarenal alpha- and beta- adrenergic receptor stimulation of renin release in the conscious dog. (
  • Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors. (
  • Mechanism of broncho-constrictor action of some adrenergic beta-receptor antagonists. (
  • A widely used non-cardioselective beta-adrenergic antagonist. (
  • The relationship between beta-adrenoceptors and adrenergic responsiveness in trout (Oncorhynchus mykiss) and eel (Anguilla rostrata) erythrocytes. (
  • The increase and its reversal both were independent of the possible presence of contaminating catecholamines in the culture medium and thus appear to reflect spontaneous beta 2AR activity and direct antagonist-receptor interactions, respectively. (
  • For this reason, beta-adrenergic antagonists may be used to relieve symptoms. (
  • In hyperthyroidism, adrenergic hyperactivity is a major cause of psychiatric symptoms, and beta-adrenergic antagonists are effective treatment. (
  • This application note describes the validation of antagonist-format CypHer5E receptor internalization assays for high-throughput screening. (
  • Effects of alpha, beta 1, and beta 2 adrenergic antagonists on. (
  • Effects of alpha, beta 1, and beta 2 adrenergic antagonists on the Na and K concentrations of sympathetic-nerve stimulated rat saliva. (
  • α-adrenergic antagonist alpha-adrenergic blocking agent . (
  • Alpha- or beta-adrenergic antagonists did not attenuate the initial rise in PRA. (
  • This increase in PRA was blocked by phentolamine, suggesting a vascular alpha-adrenergic receptor-mediated release of renin. (
  • Patients had no history of esophageal varices, variceal bleeds, or treatment with beta-adrenergic antagonists prior to their index date. (
  • Histamine 2 (H2)-receptor antagonists should be administered preoperatively to prevent increase in gastric secretion during the procedure. (
  • This suggests that an impairment of beta-adrenergic influence on GH secretion is present in anorexia nervosa. (
  • Beta-adrenergic blocking agents, beta-adrenergic antagonists, or beta antagonists. (
  • They are also sometimes known as beta antagonists, beta-adrenergic blocking agents, or beta-adrenergic antagonists. (
  • H 1 receptor antagonist any of a large number of agents that block the action of histamine by competitive binding to the H 1 receptor. (
  • beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. (